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8INTRODUCTION
Diabetic nephropathy plays an increasing role in industrialized countries as a
reason for dialysis and kidney transplantation. It is a complication of both type 1
(insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus. The
pathogenic mechanisms of diabetic nephropathy are not fully understood, but the
affecting mechanisms are probably multiple. Although hyperglycemia is the most
important cause for diabetic nephropathy, today many unresolved questions still
remain. Why do only one-third of type 1 diabetic patients develop diabetic
nephropathy? Would this complication be avoidable with perfect life-long
diabetes control? Does one major gene or do many genes predispose to diabetic
nephropathy? Why are atherosclerotic vascular diseases so common in
association with diabetic nephropathy?
This work has been carried out at the Hospital for Children and Adolescents,
University of Helsinki, and in the Department of Biochemistry, National Public
Health Institute, from 1994 to 1999. During this period, many new ideas for the
prediction and prevention of type 1 diabetic nephropathy have arisen. One
established concept is that intensive treatment of diabetes with good glycemic
control postpones and diminishes all diabetic complications (DCCT Research
Group 1993). The second trend is a movement from separate candidate gene
investigations to large family studies with transmission disequilibrium tests and
genome-wide searches (Imperatore et al. 1998; Frayling et al. 1999), or to large-
scale association studies (Risch and Merikangas, 1996). Third, an increasing
number of studies on the possible role of immune mechanisms in the
development of type 1 diabetic nephropathy have been published (Furuta et al.
1993; Hirata et al. 1998; Shibayama et al. 1999). Type 1 diabetes is an
autoimmune disease. Could the same disturbed immune mechanisms be involved
in the development of type 1 diabetic nephropathy? Diabetic nephropathy has
traditionally not been considered an immunological disease, although
immunological cells have been found in kidney biopsies. During recent years the
participation of cytokines and growth factors in the pathogenesis of diabetic
nephropathy has been shown by numerous studies (see Parving et. al. 1996a), but
the exact role of the immune response in the pathogenesis of nephropathy
remains unknown. This study concerns some of the immunological and genetic
factors associated with type 1 diabetic nephropathy.
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EPIDEMIOLOGY OF DIABETIC COMPLICATIONS
DIABETIC MICROVASCULAR COMPLICATIONS
Diabetic nephropathy
The incidence of diabetic nephropathy has declined during the last decade. In the
1980's 35 to 45% of type 1 diabetic patients were estimated to develop persistent
proteinuria after 40 years of diabetes (Andersen et al. 1983; Krolewski et al.
1985). In the 1990's, the risk of diabetic nephropathy was considerably lower:
The prevalence of proteinuria was 27% in the US population (Warram et al.
1996), and 15% in the European population after 30 years of diabetes (The
EURODIAB IDDM Complications Study Group 1994). The risk of diabetic
nephropathy seems to be higher in the USA than in the European population, a
risk also demostrated in the figures for incipient nephropathy (microalbuminuria).
In the US, the prevalences of microalbuminuria at 10 and 30 years of diabetes
were 25% and 52%, respectively (Warram et al. 1996), whereas in the European
population, the cumulative incidence of microalbuminuria was held steady
between 18 and 25% after 1 to 30 years' duration (The EURODIAB IDDM
Complications Study Group 1994).
One reason for this drop in the incidence of diabetic nephropathy is improvement
in the clinical practice of insulin treatment and therefore in glycemic control. For
example, in a Swedish center, the cumulative incidence of proteinuria was only
9% after 25 years of diabetes. These patients had had excellent mean glycated
hemoglobin for many years (Bojestig et al. 1994).
Microalbuminuria is considered a strong predictor for overt nephropathy (Viberti
et al. 1982; Mogensen and Christensen 1984). The rate of the development of
diabetic nephropathy varies in individual patients (Viberti et al. 1982), and
improvement in glycemic control may result in the disappearance of
microalbuminuria (Bojestig et al. 1996). It has been estimated that approximately
half the patients with microalbuminuria will progress to overt nephropathy
(Krolewski et al. 1996). A relative annual increase in urinary AER over 5% has
been used to distinguish progressors from non-progressors (Almdal et al. 1994).
Among progressors the median time between microalbuminuria and overt
nephropathy is about nine years (Krolewski et al. 1996).
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Microalbuminuria in prepubertal children has been rare (Kostraba et al. 1989;
Mortensen et al. 1990). In a nationwide cross-sectional study of children and
adolescents (aged 1-19 years), the prevalence of persistent microalbuminuria was
4% and of overt nephropathy 0.7% (Mortensen et al. 1990). Of the
microalbuminuric patients, only a few were prepubertal. However, in a recent
population-based longitudinal study of children diagnosed with diabetes at <5
years of age, five of 11 developed microalbuminuria before puberty (Schultz et
al. 1999). Since younger age groups are tending to develop diabetes (Karvonen et
al. 1999), prepubertal screening for microalbuminuria may become important,
due to the longer prepubertal duration of diabetes.
Risk factors for diabetic nephropathy include postpubertal duration of diabetes
(Krolewski et al. 1996), hyperglycemia (DCCT Research Group 1996),
hypertension (Parving et al. 1988; Microalbuminuria Collaborative Study Group
1992), male gender (Andersen et al. 1983), cigarette smoking (Microalbuminuria
Collaborative Study Group 1993), elevated levels of serum lipids (Coonrod et al.
1993), and familial genetic factors (DCCT Research Group 1997). The
differences in the incidences between different populations can in part be
explained by differences in these risk factors. To achieve a further decline in the
incidence figures, the presence of these risk factors should be carefully estimated
and proper treatment for each should be introduced early.
Diabetic retinopathy
Background retinopathy in diabetic patients is common. Its prevalence increases
most steeply between 5 to 15 years of diabetes duration, being about 60% after
20 years in the European population. Proliferative retinopathy means pathological
development of new vessels in the retina (neovascularization) (Aiello et al.
1998). The cumulative incidence of proliferative retinopathy rises steadily after
10 years of diabetes, being 37% at 30 years of diabetes duration (The
EURODIAB IDDM Complications Study Group 1994). The risk of proliferative
retinopathy increases twofold after onset of proteinuria (Klein et al. 1993), but its
risk can be even higher. Compared to 14% in Danish diabetic patients without
proteinuria, proliferative retinopathy had developed in 74% of matched diabetic
patients who had had proteinuria for 5 years (Kofoed-Enevoldsen et al. 1987).
The impact of hyperglycemia on the development of diabetic retinopathy was
confirmed in the Berlin Retinopathy Study in which the eyes of diabetic children
and adolescents were followed regularly from the diagnosis of diabetes by retinal
fluorescein angiography. Background retinopathy appeared after a median
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duration of 12 to 13 years when glycated hemoglobin (HbA1c) was over 9%, but
later than 25 years when HbA1c was under 8% (Danne et al. 1994).
DIABETIC MACROVASCULAR COMPLICATIONS
Diabetes is associated with a 2 to 3-fold increased risk for atherosclerotic disease
(Kannel and McGee 1979). In type 1 diabetes, cardiovascular disease has been
linked to nephropathy in many studies (Borch-Johnsen and Kreiner 1987; Jensen
et al. 1987; Krolewski et al. 1987). In a recent nation-wide Finnish study based
on hospital discharge diagnoses, the relative risk for coronary heart disease was
10-fold in type 1 diabetic patients with diabetic nephropathy compared to
patients without nephropathy. The risk for stroke was increased 11-fold in the
same study population (Tuomilehto et al. 1998).
PATHOGENESIS OF DIABETIC NEPHROPATHY
NATURAL HISTORY OF DIABETIC NEPHROPATHY
Albumin excretion rate (AER) is defined as normal at a urinary albumin
excretion of £20 µg/min. Microalbuminuria is defined as urinary AER >20
µg/min and £200 µg/min. Persistent microalbuminuria (incipient diabetic
nephropathy) is present if microalbuminuria is found in two of three consecutive
urine samples, collected preferably within 6 months (Parving et al. 1988). The
urine sample can be collected overnight or for 24 hours. Macroalbuminuria or
persistent proteinuria or overt nephropathy is defined as urinary AER >200
µg/min, or protein excretion >0.5 g during 24-hour urine collection (Mogensen
1997).
The progression of diabetic nephropathy can be divided into five stages from the
onset of diabetes until the end-stage renal failure (Mogensen et al. 1983). Stage 1
is early hyperfunction and hypertrophy, which decline after the start of insulin
treatment. Stage 2 is progression of silent morphologic lesions without signs of
clinical disease; glomerular filtration rate (GFR) is normal or increased. Stage 3
is incipient diabetic nephropathy with persistent microalbuminuria and rising
blood pressure. Stage 4, overt diabetic nephropathy, is characterized by persistent
proteinuria and decreasing GFR. This fall in GFR can be retarded by
antihypertensive medication. Stage 5 is end-stage renal failure with uremia.
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STRUCTURAL KIDNEY CHANGES AND THEIR RELATION TO
FUNCTION
Diabetes results in glomerular and interstitial structural changes demonstrated by
light and electron microscopy. Typical glomerular changes include capillary
basement thickening, and expansion of the mesangial region and matrix (Æsterby
1992). In addition, arteriolar hyalinosis and sclerosis of glomeruli are
demonstrated (Harris et al. 1991), as well as interstitial expansion (Lane et al.
1993). Structural indexes, such as basement membrane thickness, mesangial
volume fraction per glomerulus, matrix volume fraction per glomerulus (Æsterby
1992), interstitial volume fraction for total renal cortex, percentage of globally
sclerosed glomeruli, and index of arteriolar hyalinosis (Lane et al. 1993) indicate
degree of structural changes.
Structural parameters correlate with functional parameters, but large variation
exists in the structural parameters inside the functional groups (normal AER,
microalbuminuria, and overt nephropathy), as well as great overlapping between
the groups (Æsterby 1992). Structural indexes were significantly higher in
patients with microalbuminuria than in those with normal AER (Walker et al.
1992). A parallel course of mesangial and basement membrane changes occurred,
and the structural indexes correlated with urinary AER (Walker et al. 1992).
Chavers et al. (1989) found a wide range of variation in structural indexes,
including normal values, in normoalbuminuric or microalbuminuric patients
without hypertension or without decreased creatinine clearance. In a 6-year
follow-up study, the change in mesangial volume fraction per glomerulus was the
only structural parameter which correlated with increase in AER (Fioretto et al.
1995). In another 6-year prospective study of young adults with persistent
microalbuminuria, long-term AER was predicted by the degree of glomerular
structural changes (basement membrane thickness or mesangial volume fraction)
(Bangstad et al. 1999).
Glomerular basement membrane
Glomerular basement membrane (GBM) of the glomerular capillary wall is
thought to provide a major barrier against the filtration of macromolecules. The
function of this barrier is based on electrical charges. Its key component, heparan
sulphate proteoglycan (HSPG), is negatively charged through anionic sites. Thus,
negatively charged macromolecules such as albumin do not undergo filtration,
due to repelling electrostatic forces (see Vehaskari and Robson 1992). A classical
view of the increased albumin leakage in diabetic nephropathy is based on this
theory of electrical charges in GBM. In experimental diabetes, reduction in the
number of anionic sites in heparan sulphate has been shown to correlate with
increased urinary albumin excretion (van den Born et al. 1995). Anionic sites are
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reduced in diabetic patients with clinical proteinuria but not in patients with
microalbuminuria (Vernier et al. 1992).
A completely new concept challenges this theory of charge-selectivity. According
to a recent view, glomerular capillary wall is not as charge selective for albumin
as was thought, and albumin is largely filtered through this barrier (Osicka and
Comper 1998). The major part of filtered albumin is returned to the blood
circulation rapidly by what is called the high capacity pathway. The exact
location of this pathway is unknown (Eppel et al. 1999). A small amount of
filtered albumin is degraded and subsequently excreted in the urine under normal
conditions, through a pathway called the degradation pathway (Osicka et al.
2000). In early experimental diabetes, the proportion of native albumin in urine
increased, and less degraded albumin was present (Burne et al. 1998). It remains
to be seen whether other research groups confirm this theory. These findings
seem to be reasonable when related to the epidemiological finding that besides
being a marker of diabetic nephropathy, proteinuria itself may contribute to renal
damage (Parving 1998). Increased filtered protein results in an increased protein
concentration in the proximal tubular fluid, which in turn may cause tubular cell
damage (Bruzzi et al. 1997).
IMPACT OF HYPERGLYCEMIA ON THE PATHOGENESIS OF DIABETIC
NEPHROPATHY
Hyperglycemia is the major cause of diabetic nephropathy. The Diabetes Control
and Complications Trial (DCCT) showed that intensive therapy for diabetes can
reduce the risk of developing microalbuminuria and clinical albuminuria.
Intensive therapy delays the onset of microalbuminuria and albuminuria when
compared to results of conventional therapy. This treatment effect appears after 3
years for microalbuminuria, and after 5 years for albuminuria (DCCT Research
Group 1995). The effect of hyperglycemia may be mediated by several routes; of
these, activation of protein kinase C (PKC), the aldose reductase pathway (polyol
pathway), and glycoxidation (advanced glycation endproducts, AGEs) seem to be
the most important (Fig 1). Activation of PKC and the polyol pathway are
intracellular processes, whereas AGEs affect both the extracellular and
intracellular environment.
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PKC pathway Glycoxidation Polyol pathway
Glucose                              Glucose, fructose, Glucose
  glycolytic intermediates
GAP DAG
Pyruvate
Lactate
PKCé
NH2 of protein, lipid,or nucleic acid
Schiff base
Amadori product
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intermediates
AGEs
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Fructose
Fructose-3-phosphate
3-deoxyglucosoneç
Figure 1. Central pathways in the pathogenesis of diabetic nephropathy. GAP, glyceraldehyde
3-phosphate; DAG, diacylglycerol; PKC, protein kinase C; AGEs, advanced glycation end
products.
PROTEIN KINASE C
Protein kinase C (PKC) is a family of serine-threonine kinases that plays an
important role in signal transduction mechanisms (Ron and Kazanietz 1999).
PKC is the cellular receptor for the lipid second messenger diacylglycerol
(DAG), which is one of the activators of PKC, in addition to Ca2++a d phorbol
esters (Ron and Kazanietz 1999). The DAG-PKC pathway is activated in
diabetes as a result of hyperglycemia, because increased amounts of
diacylglycerol (DAG) are synthesized directly from glycolytic intermediates
(King et al. 1997). It is possible that also AGEs and oxidants increase formation
of DAG and activate PKC (Koya and King 1998).
PKC regulates many important factors related to the vascular system, such as
permeability, contractility, cellular proliferation, basement membrane synthesis,
and signal transduction for hormones and growth factors (King et al. 1997). In
diabetes, increased DAG-PKC activation has been found in the retina, aorta,
heart, and glomeruli, but not in the brain or peripheral nerves (King et al. 1997).
In diabetes, the effects of PKC are multiple. PKC decreases retinal blood flow. It
regulates renal nitric oxide production. It enhances the production of extracellular
matrix and TGF-b1 (Koya and King 1998). Evidence for the central role of PKC
in the pathogenesis of diabetic vascular complications has been obtained by study
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of PKC antagonists. In diabetic rats, a specific inhibitor of PKC b improves
GFR, AER, and retinal circulation (Ishii et al. 1996). Moreover, PKC antagonist
prevents in diabetic rats the increased mRNA expression of TGF-b1 and
extracellular matrix components in glomeruli (Koya et al. 1997). That AGEs and
angiotensin II are involved in the activation of PKC is suggested by a study
performed in streptozotocin-induced diabetic rats in which both an AGE inhibitor
and ramipril were able to inhibit an increase in glomerular PKC activity (Osicka
et al. 2000).
POLYOL PATHWAY
During hyperglycemia, the excess glucose is metabolized by the aldose reductase
pathway, also called the polyol pathway. First, glucose is converted to sorbitol by
aldose reductase. Thereafter, sorbitol is converted to fructose, and further to
fructose-3-phosphate (Kinoshita 1990). Aldose reductase inhibitors (ARI), such
as epalrestat, tolrestat, or sorbinil, inhibit the first step in the pathway. In animal
models, an ARI has been successful in diminishing proteinuria, and glomerular
hyperfiltration (Tilton et al. 1989; Bank et al. 1989; Donnelly et al. 1996). In a 6-
month study in patients with nephropathy (mean AER 291 mg/min), glomerular
filtration rate and urinary AER decreased significantly (mean AER 158 mg/min)
during ARI administration (Passariello et al. 1993); both regarded as beneficial
effects in early diabetic nephropathy.
GLYCOXIDATION
Advanced glycation end products
Advanced glycation end products (AGEs) form as a result of a complicated series
of reactions between glucose, fructose, or glycolytic intermediates and amino
groups of proteins, lipids, or nucleic acids (Brownlee 1994; Vlassara et al. 1994).
The reaction begins with glucose attachment to amino groups, thus forming a
reversible Schiff base adduct. This undergoes a slow intramolecular
rearrangement to form an Amadori product. Glycated hemoglobin, which is
clinically used to measure glycemic control is an Amadori product (de Rosa et al.
1998). The Schiff base reflects the immediate ambient glucose level, whereas an
Amadori reaction reaches the steady state level in approximately 4 weeks. This
means that in diabetes after achievement of the steady state these early
glycosylation products do not accumulate. In diabetic tissue Amadori levels are
2.5-fold compared to those in non-diabetic tissue (Bucala and Vlassara 1995).
The AGEs are formed when Amadori products react further with each other or
with other intermediates by rearrangement, condensation, and dehydration
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reactions. AGEs form stable cross-linked structures which accumulate in tissues,
especially in tissues containing proteins with a long half-life such as eye lens,
nervous and vascular tissues, and kidney (Bucala and Vlassara 1995). The AGEs
are produced even after hyperglycemia has been corrected (Vlassara et al. 1994).
Several AGEs have been characterized, such as pyrraline, pentosidine, and
carboxymethyl lysine (CML) (Bucala and Vlassara 1995). CML seems to be the
major epitope of AGEs which is recognized by experimentally induced
polyclonal AGE-antibodies, but other epitopes exist as well (Ikeda et al. 1996).
Recently, the concept of AGEs has widened considerably. Wolff et al. (1991)
proposed that metal-catalyzed oxidation of glucose itself was the major route for
AGE formation, and that other carbohydrates besides glucose, and their
metabolic intermediates, are important sources of AGEs. Baynes (1991)
emphasized the role of oxidation in the formation of AGEs. Bucala et al. (1993)
described AGE lipids. After this, a new term, "carbonyl product", was
introduced. The carbonyl product and AGE mean the same thing, and both
consist of glycoxidation and lipoxidation products (Baynes and Thorpe 1999).
The term "carbonyl stress" describes an increase in the concentration of reactive
carbonyl precursors of AGEs. These carbonyl precursors may be derived both
from oxidative and from nonoxidative reactions, and from carbohydrates and
lipids.
AGEs have profound effects on cells and tissues; they can upregulate gene
expression associated with diabetic glomerular disease, expression prevented by
an AGE inhibitor, aminoguanidine (Yang et al. 1994; Pugliese et al. 1997). AGEs
have been found in advanced glomerular lesions in human beings (Makino et al.
1995), and in proximal tubules in rats (Youssef et al. 1999). Receptors for AGEs
have been found in monocyte-macrophages, fibroblasts, and renal mesangial cells
(Vlassara 1992), in T-lymphocytes (Imani et al. 1993), in vascular smooth muscle
cells (Higashi et al. 1997), vascular endothelial cells (Stitt et al. 1999), and in
human neurons and glial cells (Li et al. 1998). AGE-receptor interaction has been
shown to mediate secretion of several cytokines and growth factors relevant to
the pathogenesis of diabetic nephropathy (Vlassara 1992).
In the glomeruli of patients with diabetic nephropathy, both early and advanced
glycation products occur (Sakai et al. 1996), and both have been considered
important in the pathogenesis of nephropathy (Cohen and Ziyadeh 1996).
Glycoxidation and peroxidation products have been found in the glomerular
lesions of patients with diabetic nephropathy (Horie et al. 1997; Suzuki et al.
1999).
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A complex interaction occurs between three metabolic pathways: the DAG-PKC
pathway, polyol pathway, and glycoxidation. For example, the breakdown
product of fructose-3-phosphate, 3-deoxyglucosone, is also an AGE intermediate,
and as such an extremely potent glycating agent (Hamada et al. 1996). In diabetic
patients with hemodialysis, one ARI was able to decrease both erythrocyte 3-
deoxyglucosone and AGE concentration (imidazolone) (Tsukushi et al. 1999).
Furthermore, polyol and DAG-PKC pathways must be associated, because an
inhibitor of aldose reductase was able to decrease PKC activity (Keogh et al.
1997).
AGEs, PKC, and the polyol pathway seem all to be important in the pathogenesis
of diabetic nephropathy. As to prevention of diabetic nephropathy, all the studies
aiming to prevent diabetic nephropathy by use of a specific inhibitor of these
pathways have been performed in experimental diabetes. When an aldose
reductase inhibitor, an AGE inhibitor, and an antioxidant were compared in
streptozotocin-induced diabetic rats, elevation of AER was prevented by an AGE
inhibitor, aminoguanidine, but not by an aldose reductase inhibitor or by an
antioxidant (Soulis-Liparota et al. 1995). However, nothing is known about the
benefit of these inhibitors in the prevention of human diabetic nephropathy, and
it remains to be seen whether an AGE inhibitor is the most beneficial or whether
a combination of many drugs would be preferable.
Oxidation and glycation of low density lipoprotein
Low density lipoprotein (LDL) has a special place in studies of glycation and
oxidation in diabetes because it is a strong risk factor for atherosclerotic vascular
diseases. LDL is the major cholesterol and cholesteryl ester carrier in plasma. It
consists of a lipid portion, including phospholipids, free cholesterol, cholesteryl
ester, and triglycerides, and a carrier protein, apoprotein (apo B-100) (Illingworth
1993). In the atherosclerotic process, circulating LDL moves into the
subendothelial space, where it is taken up by macrophages through a scavenger
receptor. In LDL overload, macrophages transform themselves into foam cells
which further change to a fatty streak (Ross 1993). Important in this respect is,
that modified LDL is taken up faster by macrophages than is native LDL.
Oxidized LDL in particular is thought to be a key molecule in atherogenesis
(Ross 1993; Witztum 1994).
In diabetic patients, glycated LDL comprises up to 21% of total LDL compared
to 5% in normal subjects (Klein et al. 1995), and the degree of glycation
correlates with glycemic control (Lyons et al. 1986). LDL of diabetic patients
with poor glycemic control is more susceptible to oxidation than is LDL of
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normal subjects (Tsai et al. 1994), but in diabetic patients with good glycemic
control the degree of LDL glycation and the susceptibility of LDL to oxidation do
not differ from those in healthy subjects (Jenkins et al. 1996).
Similarly to LDL, high density lipoprotein (HDL) is susceptible to oxidation and
glycation. In vitro oxidation of HDL has been shown to decrease its capacity to
mediate the cholesterol efflux from macrophage-derived foam cells (Nagano et
al. 1996), but in vitro glycation of HDL did not increase its susceptibility to
oxidation, or decrease its capacity to mediate cholesterol efflux (Rashduni et al.
1999).
GENETIC FACTORS IN THE DEVELOPMENT OF DIABETIC
NEPHROPATHY
General
The basis for genetic studies of risk factors for diabetic nephropathy is the
clinical fact that two-thirds of diabetic patients do not develop diabetic
nephropathy despite long-term hyperglycemia. Familial clustering of diabetic
nephropathy has been observed (Seaquist et al. 1989; Quinn et al. 1996; DCCT
Research Group 1997). Also a single pathogenetically important factor such as
hypertension clusters in families with probands with diabetic nephropathy
(Krolewski et al. 1988; Fagerudd et al. 1998). Parental history of type 2 diabetes
has also been associated with type 1 diabetic nephropathy in probands (Fagerudd
et al. 1999). Strong concordance in structural parameters of the kidney has been
apparent in siblings with type 1 diabetes (Fioretto et al. 1999).
Brownlee et al. (1986) were the first to show that an AGE-inhibitor,
aminoguanidine, could prevent diabetic complications. Later on, they formulated
a hypothesis that genetic differences in the pathways dealing with formation and
degradation of AGEs, or in the effects of AGEs on cell matrix turnover, on
cytokine and growth factor production, or on signal transduction, may be
important in susceptibility to diabetic complications (Brownlee et al. 1988).
Although Quinn et al. (1996) suggested that diabetic nephropathy may be due to
single genetic factor, more commonly diabetic nephropathy is viewed as a
multigenic disease. Several possible approaches to multigenic disorders exist:
Candidate gene studies are based on knowledge of the pathogenetic mechanisms
behind the disease. Cases and controls are compared with each other with respect
to the specific candidate gene. In type 1 diabetic nephropathy, cases are typically
patients with overt diabetic nephropathy, and controls are diabetic patients with
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normal albumin excretion despite long-duration diabetes. Genetic polymorphisms
in the candidate genes may increase or decrease susceptibility to the nephropathy.
Another approach is to study pathogenetically interesting genes occurring in
families with parents and offspring with or without diabetic nephropathy
(transmission/disequilibrium tests) (Rogus et al. 1998), and in concordant and
discordant siblings (Moczulski et al. 1998). A genome-wide search is an
interesting new method already applied in type 2 diabetic patients, affected sib-
pairs of Pima Indian origin. Scanning showed the strongest evidence for linkage
on chromosome 7q, followed by tentative evidence for linkage on chromosomes
3, 9, and 20 (Imperatore et al. 1998).
Table 1. Central polymorphisms of the renin-angiotensin system (RAS) with respect to
type 1 diabetic nephropathy.
Gene Polymorphism Alleles Genotypes
Angiotensin
converting enzyme
(ACE)
Insertion/deletion
(I/D)
I and D II, ID, DD
Angiotensinogen
(ATG)
M235àT M and T MM, MT, TT
Angiotensin II type 1
receptor (AT1)
A 166àC A and C AA, AC, CC
Evidence for  polymorphisms in the renin-angiotensin system in pathogenesis of
diabetic nephropathy
The renin-angiotensin system (RAS) consists of renin, angiotensinogen (ATG),
angiotensin I, angiotensin II, and the angiotensin II type 1 (AT1) receptor. Renin
cleaves ATG to form angiotensin I. Angiotensin-converting enzyme (ACE)
converts angiotensin I to angiotensin II, which is a potent vasoconstrictor. RAS
consists of several genetic polymorphisms. The three most investigated are
presented in Table 1. An insertion/deletion (I/D) polymorphism of the ACE gene
was first found to associate with myocardial infarction (Cambien et al. 1992), and
later on with type 1 diabetic nephropathy (Marre et al. 1994). Based on the
numerous positive (Barnas et al. 1997; Marre et al. 1997) and negative (Tarnow
et al. 1995a; Schmidt et al. 1995) studies on ACE polymorphism and diabetic
nephropathy, two meta-analyses have been appeared, one showing an association
between the D allele and diabetic nephropathy (Fujisawa et al. 1998), and the
other none (Kunz et al. 1998). An important finding is that patients with an II
genotype seem to have better response to ACE-inhibitor treatment in terms of a
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greater reduction in urinary AER than patients with an ID or DD genotype
(Penno et al. 1998; Jacobsen et al. 1998). Moreover, the D allele remained a risk
allele for cardiovascular disease in type 1 diabetic patients with nephropathy
(Tarnow et al. 1995b). In Caucasian patients with type 2 diabetes, ACE
polymorphism was not a genetic marker of diabetic nephropathy (Huang et al.
1998a) but was associated with coronary heart disease (Huang et al. 1998b).
The cleavage of ATG is the rate-limiting step in the renin-angiotensin system
(Campbell et al. 1991; Sealey and Laragh 1990). No association was found
between angiotensinogen M235T polymorphism and diabetic nephropathy
(Schmidt et al. 1996; Tarnow et al. 1996), but again contradictory studies have
been published in a case-control setting (Fogarty et al. 1996), and in a family-
based study (Rogus et al. 1998). In a non-diabetic population, the T235 allele
was associated with cardiovascular disease and hypertension (Winkelmann et al.
1999).
The polymorphic sites of an angiotensin II type 1 receptor (AT1) have also been
under investigation with both negative (Tarnow et al. 1996) and positive results,
the latter in patients with severe hyperglycemia during the first decade of diabetes
(Doria et al. 1997). In a discordant sib-pair analysis screening genes for the
renin-angiotensin system, the region containing angiotensin II type 1 receptor
showed linkage with diabetic nephropathy. This finding implicates region
surrounding AT1 on chromosome 3q as a major locus for susceptibility to
diabetic nephropathy (Moczulski et al. 1998).
Most of the studies of RAS and diabetic nephropathy are association studies in
which the central methodological problem is reliably to characterize cases and
controls (Corvol et al. 1999); if cases and controls are not reliable, false negative
results may follow. The problem is to know what appropriate factors need to be
taken into account. In the studies mentioned selection criteria for cases and
controls seem to vary considerably. In the original finding (Marre et al. 1994),
patients with microalbuminuria and overt nephropathy were compared to patients
with normal AER. The two groups were matched for retinopathy severity, which
meant that 26% of the cases showed no retinopathy. The mean duration of
diabetes was rather low, 22 years for controls and 20 years for cases. In contrast,
in studies performed at the Steno Diabetes Center in Denmark (Tarnow et al.
1995; Tarnow et al. 1996a; Tarnow et al. 1996b), only those patients with overt
nephropathy and concominant retinopathy were accepted into the case group, and
the duration of diabetes was higher, 27 years for cases and 26 for controls. These
Danish studies included hypertensive patients in both groups, while another study
excluded patients on antihypertensive medication from the control group due to
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possible effect of this medication on AER (Fogarty et al. 1996). In a later study
by Marre et al. (1997), only diabetic patients with proliferative retinopathy were
included, to ensure that the controls no longer had a risk for nephropathy. These
examples show that the criteria for patient selection for genetic studies on
diabetic nephropathy have not yet been firmly established, and thus the
interpretation and comparison of the results is difficult.
Polymorphisms in the polyol pathway and diabetic nephropathy
A gene coding for aldose reductase is located on chromosome 7q35 (Graham et
al. 1991). The aldose reductase gene contains at least two polymorphic sites, a
dinucleotide repeat polymorphism (A-C)n  (Ko et al. 1995) and a single
substitution C106T polymorphism (Kao et al. 1999). A strong association was
found between the Z-2 allele [(A-C)23 allele] of the repeat polymorphism and
type 1 diabetic nephropathy (Heesom et al. 1997), which was confirmed by Shah
et al. (1998) and Moczulski et al. (1999a). The Z-2 allele was also associated
with an increased expression of aldose reductase mRNA in peripheral blood
mononuclear cells (Shah et al. 1998). In contrast, patients with type 2 diabetes
with normal albumin excretion, microalbuminuria, and proteinuria in regard to
dinucleotide repeat polymorphism and nephropathy showed a negative result
(Moczulski et al. 1999b).
Interleukin-1 and diabetic nephropathy
Interleukin-1 (IL-1) forms a family of three proteins, IL-1a, IL-1b, and the IL-1
receptor antagonist  (IL-1ra) produced by mononuclear cells, endothelial cells,
and many other cells. IL-1a and IL-1b are potent enhancers of immune responses
such as T-cell activation and proliferation and cytokine secretion. IL-1a and IL-
1b also induce acute inflammatory response, including fever, anorexia, myalgia,
and synthesis of C-reactive peptide. IL-1ra is a natural antagonist of IL-1a a d
IL-1b which regulates the course of this inflammation. (Rosenwasser 1998). IL-1
stimulates mesangial cell proliferation and extracellular matrix production
(Melcion et al. 1982). Type 1 diabetic patients with overt nephropathy showed
significant difference in frequency of interleukin 1B*2 allele as compared to
patients with normal AER (Loughrey et al. 1998). However, an earlier Danish
study was negative with respect to the IL-1 family and diabetic nephropathy
(Tarnow et al. 1997). A notable difference between the two study populations
was that 48% cases of the former study had end-stage renal failure, and 36%
impaired renal function, whereas in the latter, the highest creatinine was 684
mmol/L, suggesting that patients in the former study had more advanced diabetic
nephropathy.
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Transforming growth factor-b1 and diabetic nephropathy
Transforming growth factor-b1 (TGF-b1) is a central growth factor in fibrotic
diseases (see pages 25-26). A gene encoding transforming growth factor-b1
(TGF-b1) is located on chromosome 19q13 (Lawrence 1995) contains several
polymorphic sites. A Pro25Arg polymorphism was linked to blood pressure in
healthy European males (Cambien et al. 1996). A Thr263Ile mutation was
associated with diabetic nephropathy in type 1 diabetic patients (Pociot et al.
1998). TGF-b1 plasma levels were associated with blood pressure in patients
with end stage renal disease (Li et al. 1999).
N-acetyltransferase-2 and diabetic nephropathy
N-acetyltransferases 1 and 2 are cytosolic enzymes which transfer acetyl groups.
Both are located at the same gene locus on chromosome 8 (Blum et al. 1990).
Each metabolizes distinct arylamine drugs and carcinogens. NAT2 is operative in
liver cell cytosols and is also expressed in the small intestine, colon, esophagus,
bladder, ureter, stomach, and lung (Windmill et al. 1997), whereas the
distribution of NAT1 is more widespread in the body. NAT1 was thought to be a
monomorphic enzyme until 1993, when a genetic polymorphism of NAT1 was
found (Vatsis and Weber 1993). The polymorphism of NAT2 has been known for
over 40 years (Evans et al. 1960). Drugs such as hydrazine, hydralazine,
salazosulfapyridine, procainamide, isonizid, and caffeine are metabolized either
slowly or rapidly depending on the inherited NAT2 genotype (Evans 1989). At
least 12 different alleles of the NAT2 gene are known, which are mainly slow
allele mutations of the dominant fast allele (Vatsis et al. 1995). Foreign
substances metabolized by NAT2 include benzidine, and b- aphtylamine, a
tobacco-smoke derivative.
Traditionally, the NAT2 phenotype has been determined from a urine or a plasma
sample after a single oral dose of sulfametazine, dapsone, or caffeine, and the
metabolic ratio of unacetylated and acetylated drug calculated (Evans 1989). In
the past decade, genotyping has become the principal test method to detect fast
and slow acetylators (Doll et al. 1995; Agúndez et al. 1996). A marked
interethnic variation is found in the distribution of fast and slow acetylators. For
example, among Eskimos and Arabs, slow acetylators predominate (80-90%),
whereas in Japan over 90% are fast acetylators. Among Caucasians, slow
acetylators are 50 to 60% of the population (Evans 1989). This interethnic
variation is due to differing frequencies of mutations in the NAT2 gene (Lin et al.
1993; Lin et al. 1994).
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In early studies an increased prevalence of fast acetylators was observed in
patients with type 1 diabetes (Evans 1984). However, the series were small, and
the conclusions were based on the combination of several studies (Bodansky et
al. 1981). It is possible that in these studies, the diabetic state has influenced the
metabolic ratio used for the distinction between slow and fast acetylators.
Recently, in patients with type 2 diabetes, the onset of insulin treatment
decreased the acetylation capacity of sulfamethazine, suggesting that the poor
metabolic control before the start of insulin treatment had increased NAT2
activity by enzyme induction (Lautenschlager et al. 1996). In contrast, a study of
type 1 diabetic patients on two occasions with different HbA1c levels suggested
that the improvements in glycemic control increased NAT2 activity (Bechtel et
al. 1988). In patients with type 2 diabetes, fast acetylators showed higher fasting
insulin and first-phase insulin peak values during intravenous glucose tolerance
test than did slow acetylators (Burrows et al. 1978). In young patients with type 1
diabetes, 15 patients of 16 with early microalbuminuria were slow acetylators
(Madácsy et al. 1992). From the above studies, it can thus be concluded that a
link may exist between NAT2 and diabetes. NAT2 gene alleles have not
previously been studied in patients with established type 1 diabetic nephropathy.
HEMODYNAMIC FACTORS IN THE PATHOGENESIS OF DIABETIC
NEPHROPATHY
The overall prevalence of 15% for systemic hypertension in type 1 diabetes is
mainly associated with incipient and overt nephropathy, because in patients with
normal AER the prevalence of essential hypertension corresponds to that of the
general population (4%) (Norgaard et al. 1990). During the transition phase from
normal AER to microalbuminuria, early changes in blood pressure are already
possible to find by ambulatory blood pressure monitoring (Poulsen et al. 1994).
Hypertensive diabetic patients have increased total body sodium content and
vascular resistance. During incipient nephropathy sodium retention and
extracellular fluid volume load both increase, which further elevates the blood
pressure (Arauz-Pacheco and Raskin 1996).
Diabetes causes intraglomerular hemodynamic changes (hyperfiltration and
increased intraglomerular pressure and renal plasma flow) which can be stronger
when systemic hypertension is present (Hostetter et al. 1982). High
intraglomerular pressure induces mesangial stretch which during hyperglycemia
increases production of TGF-b1 and collagen (Riser et al. 1998).
During overt nephropathy, the rate of decline in GFR can be effectively retarded
by antihypertensive drugs (Parving et al. 1987). Urinary albumin excretion, as
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well, decreases with antihypertensives (Parving and Rossing 1994).
Angiontensin-converting enzyme (ACE) inhibitors may have other renoprotective
effects in addition to the effect resulting from blood pressure lowering (Björck et
al. 1992; Rumble et al. 1995), probably through the inhibition of the growth-
promoting effect of angiotensin II (Wolf 1995). In the future, calcium antagonists
may prove as useful as ACE inhibitors in renoprotection (Parving et al. 1996b).
Even beta-blockers may be useful, since in young microalbuminuric patients
glomerular structural changes did not progress after the start of enalapril or
metoprolol treatment (Rudberg et al. 1999).
ENDOTHELIAL DYSFUNCTION AND INSULIN RESISTANCE IN
ASSOCIATION WITH DIABETIC NEPHROPATHY
The endothelium covers the inner surface of all blood vessels. It regulates the
adherence of leukocytes and platelets to the vessel wall, controls permeability of
the vessel wall to macromolecules and regulates vascular tone (Haller 1997).
Vascular tone is regulated by secretion of vasodilatating agents such as nitric
oxide (NO) and prostaglandins. Damaged endothelial cells can secrete
vasoconstricting agents such as endothelin-1 (ET-1) and thromboxane (Haller
1997) with disturbed balance between vasodilating and vasoconstricting factors
being one marker of endothelial dysfunction. Degree of endothelial dysfunction
can be estimated by plasma markers such as von Willebrand factor, endothelin-1,
and plasminogen activator inhibitor type 1 (PAI-1) (Vischer et al. 1998; Huvers
et al. 1999), or by use of a forearm vasodilatation test. One feature of diabetic
microangiopathy is endothelial dysfunction (La Selva et al. 1993), which in type
1 diabetes precedes the onset of microalbuminuria (Stehouwer et al. 1995).
Endothelial dysfunction is associated with insulin resistance, and hyperglycemia
contibutes to both via differing mechanisms (Mäkimattila et al. 1996a). Glycated
LDL may indirectly contribute to endothelial dysfunction, because it reduces NO
synthesis and bioactivity and consequently the vasodilatory response seen in
diabetes (Posch et al. 1999).
A variable degree of insulin resistance is typical of patients with type 1 diabetes
(Yki-Järvinen and Koivisto 1986), resistance induced by hyperglycemia
(Vuorinen-Markkola et al. 1992), and causing difficulties in glucose extraction
(Mäkimattila et al. 1996b). Insulin resistance can be normalized by physical
training (Yki-Järvinen et al. 1984). In type 1 diabetes, insulin resistance is
associated with microalbuminuria (Yip et al. 1993) and precedes the latter
(Ekstrand et al. 1998).
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GROWTH FACTORS IN THE PATHOGENESIS OF DIABETIC
NEPHROPATHY
Transforming growth factor-b1
With respect to diabetic nephropathy, transforming growth factor-b (TGF-b) is
one important growth factor. Several reviews emphasize its position as a key
mediator in diabetic nephropathy (Sharma and Ziyadeh 1995; Border et al. 1996;
Sharma and Ziyadeh 1997a; Gilbert and Cooper 1999). The three mammalian
isoforms of TGF-b, TGF-b1, TGF-b2, and TGF-b3 show a 70 to 80% sequence
identity. Mature TGF-bs are all 25 kD homodimers with 112 amino acids in each
monomer (Lawrence 1995). Since most research performed on diabetic
nephropathy deals with TGF-b1, the focus here is on this isoform.
TGF-b1 is synthesized as a large precursor molecule which is cleaved by furin
convertase into two parts, TGF-b1 and the precursor peptide; these two associate
non-covalently with each other (Dubois et al. 1995). The precursor peptide is
called a latency-associated peptide (LAP) and has an important function in
maintaing latency of TGF-b1. Another protein, latent TGF-b1-binding protein
(LTBP) usually associates with LAP. Thus, TGF-b1 is secreted from the cells as
a large inactive complex which contains both LAP and LTBP. The activity of
TGF-b1 is controlled extracellularly (Crawford et al. 1998). Most cultured cells
secrete TGF-b1, including fibroblasts, lymphocytes, macrophages, and
endothelial cells. Platelets contain a large reservoir of TGF-b1, and it is also
found in the kidney (Roberts and Sporn, 1992).
The biological actions of TGF-b1 are multiple. TGF-b1 displays an
antiproliferative action by lengthening or arresting the cell-cycle G1 phase.
Through an antiproliferative action on B- and T-lymphocytes, TGF-b1 shows
immunosuppressive activity. TGF-b1 enhances synthesis and deposition of
extracellular matrix, as well as decreases its proteolysis. It controls cell adhesion
receptor expression and cell differentiation (Massague 1990). The ability of
TGF-b1 to induce progressive tissue fibrosis is explained by an exaggerated
prolonged response to an injury which is caused by sustained production of TGF-
b1 (Border and Noble 1994).
High ambient glucose concentration enhances TGF-b1 production through
stimulation of the transcription rate of mRNA, the total TGF-b1 protein
production and its bioactivity (Hoffman et al. 1998). In kidney cell cultures, high
glucose stimulates TGF-b1 production in proximal tubular epithelial cells (Rocco
et al. 1992), in cortical fibroblasts (Han et al. 1999), in mesangial cells (Ziyadeh
et al. 1994), and in glomerular visceral epithelial cells (podocytes) (van Det et al.
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1997). In addition, glomerular endothelial cells are capable of TGF-1
production (Wolf et al. 1999). TGF-b1 production is also stimulated by
angiotensin II (Wolf et al. 1993), mesangial stretch (Riser et al. 1998), and AGEs
(Pugliese et al. 1997).
In rat experimental diabetes, increased glomerular staining for TGF-b1 protein
correlated with albuminuria (Bertoluci et al. 1996). Increased expression of TGF-
b1 protein and mRNA was found in renal tubules, and this tubular expression of
TGF-b1 associated with signs of tubulointerstitial injury (Gilbert et al. 1998a). In
human beings, strong staining for TGF-b1 was observed in glomeruli from six
patients with advanced diabetic nephropathy (Yamamoto et al. 1993). In addition,
in five patients with diabetic nephropathy, significant increases occurred in the
immunoreactivity of all three isoforms of TGF-b both in the glomeruli and
tubulointerstitium (Yamamoto et al. 1996). In 29 patients with type 2 diabetic
nephropathy, intraglomerular TGF-b1 mRNA was increased and correlated with
HbA1c (Iwano et al. 1996).
Studies in man are few, because kidney biopsies are rarely performed in type 1
diabetic patients with normal AER or microalbuminuria, or even with overt
diabetic nephropathy. For diabetic nephropathy urinary excretion of TGF-b1 can
be regarded as a potential non-invasive marker (see also page 33). Urinary TGF-
b1 seems to reflect TGF-b1 production in the kidney (Sharma et al. 1997b). In
various studies of human glomerular diseases, urinary excretion of TGF-b1 has
been associated with interstitial fibrosis (Murakami et al. 1997), progression of
glomerular disease (Honkanen et al. 1997), and mesangial expansion (Sato et al.
1998). By performance of regular kidney biopsies in the early phases of human
diabetic nephropathy with simultaneous urinary TGF-b1 measurements,
important information about the role of TGF-b1 in the pathogenesis of
nephropathy is likely to be obtained. The amount and localization of TGF-b1,
whether in the tubulointerstitium, mesangium, or basement membrane, when
compared to urinary excretion of TGF-b1, may provide valuable new
information.
Insulin-like growth factor
Insulin-like growth factor-1 (IGF-1) shows a 50% sequence homology with
proinsulin. IGF-1 contributes to the regulation of glomerular filtration rate and in
diabetes to the renal hypertrophy (Hirschberg and Adler 1998). Mesangial cells
from diabetic NOD mice secrete an increased amount of IGF-1 (Elliot et al.
1993). In the same cells, collagen degradation is decreased by IGF-1 (Lupia et al.
1999). Moreover, incubation of human or rat mesangial cells with one AGE,
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bovine serum albumin-AGE, resulted in markedly increased production of IGF-1
(Pugliese et al. 1997). In young patients with type 1 diabetes, urinary IGF-1 has
been associated with kidney volume. Levels of urinary IGF-1 and growth
hormone were higher in patients with microalbuminuria than in patients with
normal AER (Cummings et al. 1998). Growth hormone is an important regulator
of IGF-1. A new growth hormone antagonist has prevented the rise in kidney
IGF-1, kidney weight and glomerular volume in experimental diabetes (Flyvbjerg
et al. 1999).
Platelet-derived growth factor
Platelet-derived growth factor (PDGF) is a key regulator of connective tissue
cells. PDGFs are dimers of A- and/or B-chains with PDGF-B up-regulated in
atherosclerotic lesions (Betsholtz and Raines 1997). In mice deficient for PDGF-
B, kidney mesangial cells were completely lacking, with only a single or just a
few dilatated capillary loops and practically no urinary space present (Betsholtz
and Raines 1997). PDGF has been shown to increase extracellular matrix
production in the glomerulus (Johnson et al. 1992). However, in a model of a
hyperglycemic GK rat which does not spontaneously develop nephropathy,
PDGF treatment did not cause diabetic nephropathy (Riley et al. 1999). In
cultured human mesangial cells, high glucose induced increased expression of
PDGF, which further activated TGF-b1 gene expression (Di Paolo et al. 1996).
In rats with one kidney removed, increased glomerular capillary pressure led to
increased mRNA levels for PDGF and TGF-b1 (Shankland et al. 1994). Urinary
PDGF was increased in patients with microalbuminuria or overt diabetic
nephropathy when compared to patients with normal AER (Fagerudd et al. 1997).
No other PDGF studies are available concerning humans with diabetic
nephropathy.
Fibroblastic growth factor
Fibroblastic growth factor (FGF-2 or basic FGF) is a multifunctional growth
factor thought to be involved in vascular homeostasis, atherosclerosis, wound
healing, and angiogenesis (Gospodarowicz 1991). In normal human kidney it is
expressed most consistently in glomerular parietal epithelial cells, distal tubular
cells, and arterial endothelial cells (Floege et al. 1999). The expression of FGF-2
in diabetic kidney has not been studied. FGF-2 and TGF-b1 can interact with
each other. FGF-2 stimulates the release of preformed, latent TGF-b1 in cultured
proximal tubular cells (Phillips et al. 1997). In the same way, TGF-b1
upregulates the production of FGF-2 in cultured proximal tubular cells (Jones et
al. 1999). Daily intravenous FGF-2 increases podocyte damage, proteinuria, and
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glomerulosclerosis in rats with membranous nephropathy (Floege et al. 1995),
suggesting a significant role for FGF-2 in damage to the filtration barrier, but in a
hyperglycemic rat model, FGF-2 treatment has caused no diabetic nephropathy
(Riley et al. 1999).
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is an important growth factor in the
pathogenesis of diabetic retinopathy (Gilbert et al. 1998; Hammes et al. 1998;
Smith et al. 1999), but few studies have been performed in diabetic nephropathy.
A rat model of type 2 diabetic nephropathy demonstrated overproduction of
VEGF (Tsuchida et al. 1999). Streptozotocin-induced diabetes was also
associated with increased renal VEGF gene expression (Cooper et al. 1999).
IMMUNOLOGICAL FACTORS AND DIABETIC NEPHROPATHY
Several studies suggest the involvement of immunological cells in the
pathogenesis of diabetic nephropathy. Bending et al. (1988) studied DR-positive
T-lymphocytes from peripheral blood in patients with and without diabetic
nephropathy. In patients with non-nephrotic-range proteinuria, a higher
percentage of T-lymphocytes were activated than in patients without proteinuria
but of same diabetes duration. T-lymphocytes have been found in the
juxtaglomerular bodies of type 1 diabetic patients (Paulsen et al. 1994). In
experimental diabetic nephropathy, an early increase of platelets appeared in
glomeruli of diabetic rats, followed by a prominent macrophage infiltration from
day 3 to a peak at day 30 (Young et al. 1995). In patients with type 2 diabetes, a
transient infiltration of macrophages was observed during moderate diabetic
glomerulosclerosis (Furuta et al. 1993). Furthermore, increased expression of P-
and E-selectins was found in the glomeruli and interstitium of patients with type
2 diabetic nephropathy (Hirata et al. 1998). In a large series of patients with type
1 diabetic nephropathy, kidney biopsies often showed interstitial inflammation
with infiltrated monocytes, macrophages, T-lymphocytes, fibroblasts, and
fibrocytes in the interstitium (Bohle et al. 1991). The 5- and 10-year survival
rates were best in patients with a normal appearance of the cortical interstitium
(Bohle et al. 1991). Only a few studies have been published on this issue, and the
role of the kidney-infiltrating T-cells remains open in diabetic nephropathy. The
antigen-specificity of these T cells is unknown.
Two cytokines, secreted by immunological cells and relevant to diabetic
nephropathy, are interleukin-1 (IL-1, see also page 20) and tumor necrosis factor
(TNF). These cytokines have been studied in connection with AGEs. The
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removal of AGEs by macrophages was associated with the release of interleukin-
1 (IL-1) and tumor necrosis factor (TNF) (Vlassara et al. 1988). In addition, TNF
has enhanced several-fold the removal of AGEs by monocytes and macrophages
by upregulating the receptor for AGEs (Vlassara et al. 1989). An AGE-induced
effect is also suggested by the fact that GBM material isolated from diabetic rats
induced elevated TNF and IL-1 secretion from cultured rat peritoneal
macrophages, in contrast to GBM material of control rats or aminoguanidine-
treated diabetic rats (Hasegawa et al. 1991). Recently, plasma TNF levels have
correlated with glycemic control in type 1 diabetic patients (Lechleitner et al.
1999), and with proteinuria in type 1 diabetic patients with advanced diabetic
nephropathy (Navarro et al. 1999). Both these cytokines have been found to act
together with TGF-b1. IL-1b has induced TGF-b1 production in cultured
proximal tubular cells when the cells were primed in hyperglycemic medium
(Phillips et al. 1996). The combination of IL-1b and TGF-b1, or TNF-a and
TGF-b1 had a synergistic effect on rat mesangial-cell fibronectin production
(Pawluczyk and Harris 1998). These studies suggest that these cytokines
produced by immunological cells may interact with growth factors produced by
kidney cells.
The significance of autoantibodies in the pathogenesis of diabetic nephropathy is
unclear. However, analogous mechanisms between atherosclerosis and
glomerulosclerosis suggest the involvement of an autoimmune process (Diamond
1991). It has been observed that any simple modification of a protein can evoke
autoantibody production (Steinbrecher et al. 1984). Thus, early glycation of a
protein (Amadori formation) may cause an immune response (Witztum et al.
1983). Antibodies to glycated proteins have been found in diabetic patients.
These antibodies bind to a common glucitol-lysine epitope (Witztum et al. 1984).
In rats, preimmunization with glycated albumin led to an acceleration of diabetic
nephropathy (Bassiouny et al. 1985).
In type 1 diabetic patients with microangiopathy, antibodies to oxidized LDL
were lower than in patients without microangiopathy (Festa et al. 1998). In type 1
diabetes, antibodies to oxidized LDL were inversely related to coronary artery
disease (Orchard et al. 1999). These studies raise the issue of the possible
importance of oxidized LDL-containing immune complexes in the pathogenesis
of diabetes-related vascular complications rather than free autoantibodies (Lopes-
Virella et al. 1999). Recently an autoantibody to an AGE (CML) was found
which was associated with end-stage diabetic nephropathy or non-diabetic kidney
failure (Shibayama et al. 1999).
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ENVIRONMENTAL FACTORS IN THE PATHOGENESIS OF DIABETIC
NEPHROPATHY
Diet
Increased protein content of the diet causes increased protein traffic across the
glomerular capillary, especially during microalbuminuria and overt nephropathy,
traffic which induces damage in proximal tubular cells (Remuzzi et al. 1997;
Bruzzi et al. 1997). A low-protein diet retards the progression of diabetic
nephropathy by decreasing proteinuria and diminishing the decline in glomerular
filtration rate (Hansen et al. 1999; Pedrini et al. 1996). Foods contain dietary
glycotoxins, which readily react with AGE intermediates in the body to form
AGEs. Browned, protein-rich food prepared with sugar are especially harmful in
this respect. A roasted duck skin and a cake made in the oven at a high
temperature have very high AGE contents (Koschinsky et al. 1997). Food with
excessive fat may increase cholesterol and LDL which are associated with
diabetic nephropathy and atherosclerosis (Groop et al. 1996). A vegetarian diet
may be beneficial in preventing LDL oxidation (Korpela et al. 1999). Phenolic
compounds of olive oil, and purple grape juice may decrease the susceptibility of
LDL to oxidation (Caruso et al. 1999; Stein et al. 1999). Vitamins E and C may
be useful in the prevention of diabetic nephropathy (Craven et al. 1997; Jain et al.
1999). Reduced sodium content of the diet may also be beneficial to the kidneys
(Allen et al. 1997; Mülhauser et al. 1996a), especially after onset of
microalbuminuria (Trevisan et al. 1998).
Smoking
In patients with type 1 diabetes, smoking increases all-cause and cardiovascular
mortality (Moy et al. 1990; Rossing et al. 1996), but its significance as a risk
factor for diabetic nephropathy is more complex. In some studies, smoking
associates with the progression of type 1 diabetic nephropathy (Sawicki et al.
1994; Mühlhauser et al. 1996b), or type 2 nephropathy (Biesenbach et al. 1997;
Forsblom et al. 1998). In other studies, smoking did not associate with the
progression of nephropathy (Orchard et al. 1990; Gall et al. 1997). Since smoking
is an established risk factor for atherosclerosis, and diabetic nephropathy is
associated with macrovascular atherosclerotic disease, one would expect smoking
to promote diabetic nephropathy. One possible explanation for the discrepancy is
individual variation in the elimination of tobacco smoke substances. Tobacco
smoke contains thousands of substances (Hoffmann and Wynder 1986; Marques
and Beland 1994; Fischer et al. 1991), and several polymorphically distributed
enzymes, such as NAT2 and NAT1 and cytocrom P 450 enzymes, participate in
the metabolism of these substances. Tobacco smoke also contains reactive
glycation products which can rapidly react with proteins to form AGEs (Cerami
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et al. 1997). Increased levels of AGEs have been found in the lenses and blood
vessels of smokers (Nicholl et al. 1998). Smoking does not, however, seem to
worsen endothelial sensitivity (Helve et al. 1986).
PREDICTION OF DIABETIC NEPHROPATHY
At present it is impossible reliably to predict who of the young diabetic patients
with normal AER will progress to diabetic nephropathy during their lifespan.
Although intensive treatment and good metabolic control reduces the risk for
diabetic nephropathy significantly (DCCT Research Group 1995), good
metabolic control is not always achievable. It would be of considerable value if
risk for diabetic nephropathy could be predicted at an early stage, and a special
effort could be focused on those especially at risk.
URINARY MARKERS FOR DIABETIC NEPHROPATHY
Several urinary proteins and enzymes supplement urinary albumin as markers for
diabetic nephropathy, a topic reviewed recently. These markers can be divided
into glomerular, tubular, and other types of markers (Hong and Chia 1998).
Albumin is traditionally considered a marker for glomerular dysfunction, and a1-
microglobulin a marker for tubular dysfunction.
Albumin
After onset of microalbuminuria, the risk of progressing to diabetic nephropathy
is about 50%  (Krolewski et al. 1996). This risk may, however, vary greatly
between different age groups (Couper et al. 1997), or at different levels of
glycemic control (Bojestig et al. 1996), or after differing durations of diabetes
(Forsblom et al. 1992). To identify those who will develop microalbuminuria is
even more difficult. Baseline AER and glycated hemoglobin were the best
independent predictors for microalbuminuria during a 10-year follow-up
(Mathiesen et al. 1995). The rate of annual increase in AER seems to be
important for prognosis (Almdal et al. 1994), as are borderline or intermittent
increases in AER (Couper et al. 1997). As a common laboratory test, urinary
albumin remains thus far the most useful predictive marker for diabetic
nephropathy.
a1-microglobulin
a1-microglobulin is a low-molecular-weight plasma protein easily filtered in the
glomerulus and reabsorbed in the proximal tubulus. Its amount in urine reflects
tubular reabsorptive capacity of small plasma proteins. Its measurement in urine
is useful for diagnosing tubular proteinuria in various clinical conditions (Itoh
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and Kawai 1990). Simultaneous measurement in serum and urine allows
detection of decreased GFR at early stages (Itoh and Kawai 1990). Urinary a1-
microglobulin is increased in children with type 1 diabetes and correlates with
glycosylated haemoglobin (Walton et al. 1988). A 7-year prospective study
showed urinary a1-microglobulin not to be predictive for microalbuminuria in
young patients with type 1 diabetes (Kordonouri et al. 1998).
N-Acetyl-b-D-glucosaminidase
N-Acetyl-b-D-glucosaminidase (NAG) is a tubular lysosomal enzyme. Urinary
NAG excretion developed before microalbuminuria in a 7-year follow-up study
of type 1 diabetic children and adolescents with normal AER. If NAG levels
remained low, none of the patients progressed to microalbuminuria, but all
patients with increased NAG developed later microalbuminuria (Kordonouri et
al. 1998).
TGF-b1
Urinary TGF-b1 has been studied in experimental kidney diseases and in patients
with non-diabetic and diabetic kidney diseases. Urinary excretion of TGF-b1
correlates with degree of glomerulosclerosis and interstitial fibrosis in rats with
subtotal renal ablation (Monteiro et al. 1998). In patients with
glomerulonephritis, urinary TGF-b1 activity associated with structural and
functional renal changes (Dominguez et al. 1998). In patients with type 2
diabetes, urinary TGF-b1 excretion was higher in patients with severe mesangial
expansion than in patients with low mesangial expansion (Sato et al. 1998).
Urinary TGF-b1 was elevated in adult type 1 diabetic patients but could not
distinguish between patients with normal AER, microalbuminuria, or overt
nephropathy (Fagerudd et al. 1997). No studies have been performed in children
and adolescents with type 1 diabetes in regard to urinary TGF-b1.
BLOOD MARKERS FOR DIABETIC NEPHROPATHY
Serum AGE and carboxymethyl lysine levels were increased in children and
adolescents with type 1 diabetes (Berg et al. 1997a; Berg et al. 1998a). In a study
by Chiarelli et al. (1999a), serum AGEs were markedly increased in adolescents
and young adults with early microvascular complications. In addition, serum
AGE levels predicted morphological changes in kidney during a 2.5-year follow-
up (Berg et al. 1997b).
Erythrocyte sodium-lithium countertransport (Na+/Li+ CT) activity is associated
with hypertension and hyperlipidemia in the general population (van Norren et al.
1998). When diabetic patients have been divided into two groups based on their
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individual Na+/Li+ CT activity, elevated sodium-lithium countertransport levels
have predicted microalbuminuria with a sensitivity of 85% and a specificity of
55% (Monciotti et al. 1997). Elevated Na+/Li+ CT activity may help to identify
children and adolescents at risk for microalbuminuria (Chiarelli et al. 1999b).
These urinary or blood markers do not yet compete with urinary albumin in
predicting diabetic nephropathy, because prospective studies thus far are few. In
the future, a combination of genetic, urinary, and blood markers may serve
together for risk profile estimation for diabetic nephropathy analogous to risk
profile estimation for coronary artery disease (Wood et al. 1998).
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AIMS OF THE STUDY
The aims of the study were
(I) to investigate the role of N-acetyltransferase-2 (NAT2) polymorphism as a
candidate gene for type 1 diabetic nephropathy,
(II) to study the occurrence of antibodies to oxidized and glycated LDL in adult
type 1 patients with and without diabetic nephropathy and their role as a marker
for nephropathy-related atherosclerosis,
(III) to study the activation of transforming growth factor-b1 (TGF-b1) in
peripheral blood mononuclear cells from type 1 diabetic patients with and
without diabetic nephropathy,
(IV) to study urinary transforming growth factor-b1 and a1-microglobulin
excretion in children and adolescents with type 1 diabetes.
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PATIENTS AND CONTROLS
The four Studies included adult patients with and without type 1 diabetic
nephropathy (I, II, III), children and adolescents with type 1 diabetes (I, IV), and
healthy control subjects (I-IV) (Table 2). Studies I and II included British and
Finnish adult type 1 diabetic patients and controls (Guy's Hospital, London and
Department of Medicine, University of Helsinki, Helsinki), and Study I also
young type 1 diabetic patients (Hospital for Children and Adolescents, University
of Helsinki). Study III included Finnish type 1 diabetic patients and controls from
the Department of Medicine, University of Helsinki, and Study IV type 1 diabetic
children and adolescents from the Hospital for Children and Adolescents,
University of Helsinki, and from the Aurora Hospital, Helsinki.
Table 2. Study populations of Studies I-IV.
Study Normo Micro DN Control ACE
inhibitor
Normo/
Micro/DN
I n (m/f)
B/F
83 (42/41)
26/57
58 (35/23)
29/29
73 (41/32)
17/56
53 (29/24)
24/29
0/3/8
I n (m/f) 70 (36/34)5 (3/2) - - 0/2/-
II* n (m/f)
B/F
64 (31/33)
27/37
52 (35/17)
30/22
37 (17/20)
18/19
54 (30/24)
25/29
0/3/10
III n (m/f) 30 (13/17)12 (6/6) 10 (6/4) 13 (6/7) 3/10/8
IV n (m/f) 105 (50/55) 8 (6/2) - 39 (17/22)0/2/-
B, British; F, Finnish
Normo, normal albumin excretion rate; Micro, microalbuminuria; DN, overt diabetic
nephropathy
* Includes also 52 microalbuminuric patients
The clinical characteristics of patients and controls are presented in Table 3. The
current stage of diabetic nephropathy was defined according to the median AER
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of two to three overnight urine collections. The normoalbuminuric patients had a
median AER less than 20 µg/min. The microalbuminuric patients had a median
AER between 20 and 200 µg/min, and the nephropathic patients over 200
µg/min, or they were being treated by dialysis for end-stage renal disease.
Table 3. Clinical characteristics of patients and controls. Data presented as means±SD
except for AER median (range).
StudySubjects Age (years)Duration
of diabetes
(years)
Glycated
hemoglobi
n
(%)
AER rate
(mg/min)
I Diabetic patients
with:
Normal AER
Microalbuminuria
Diabetic nephropathy
Healthy controls
37.5±10.5
39.3±11.7
39.7±8.5
38.6±10.3
21.6±8.8
23.7±8.9
26.4±7.6
-
9.4±1.6 a
9.8±1.5 a
9.9±1.6 a
6.1±0.5a
6 (0-19)
53 (6-192)
537 (48-3160)
4 (0-9)
I Diabetic patients
with:
Normal AER
Microalbuminuria
13.1±3.2
15.4±2.8
6.3±2.3
10.5±2.8
9.3±1.5 b
10.3±2.1 b
4 (1-17)
52 (20-196)
II Diabetic patients
with:
Normal AER
Microalbuminuria
Diabetic nephropathy
Healthy controls
37.6±10.1
40.3±11.8
37.8±8.6
38.6±10.2
22.5±8.6
24.2±9.2
24.4±7.1
-
9.4±1.6 a
9.8±1.5 a
9.7±1.5 a
6.0±0.6 a
7 (0-19)
53 (20-192)
433 (48-1756)
4 (0-9)
III Diabetic patients
with:
Normal AER
Microalbuminuria
Diabetic nephropathy
Healthy controls
40.5±9.7
39.5±9.0
36.6±8.9
33.9±8.7
28.0± 7.3
28.3±8.6
28.0±7.7
-
8.3±1.3 b
8.6±1.6 b
8.9±1.5 b
-
5 (2-19)
75 (22-198)
308 (217-682)
-
IV Diabetic patients
with:
Normal AER
Microalbuminuria
Healthy controls
13.9±2.8
16.8±3
13.8±2.8
7.2±2.8
10.1±3.0
-
9.3±1.4 b
9.9±1.9 b
-
5 (2-19)
35 (20-196)
3 (1-29)
a HbA1
b HbA1c
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For Study I NAT2 genotype was analyzed from the adult diabetic patients with
and without nephropathy, while young Finnish type 1 diabetic patients were
recruited for the parallel NAT2 genotype and phenotype analysis. Twenty-nine
nephropathic patients were on dialysis. Smoking habits were asked by the study
physician during the clinical investigation. Non-smokers were either never-
smokers, or had a short smoking history (less than 12 years). Current smokers as
well as those responding as non-smokers but having smoked over 12 years were
classified as smokers. Of the adult normoalbuminuric patients 23% were
smokers, of the microalbuminuric 42%, of the nephropathic 34%, and of the
control subjects 28% (no difference between the groups). Six young patients
(8%) smoked at least five cigarettes per day.
Study II included the bulk of adult diabetic patients from Study I. All participants
had normal renal function with a serum creatinine concentration below 110
µmol/l. Patients taking diuretics or betablockers were excluded. None of the
normoalbuminuric patients nor any of the healthy subjects took antihypertensive
medication. Three microalbuminuric patients were on ACE inhibition, and one
was taking a Ca-channel blocker. Seven nephropathic patients were being treated
with ACE-inhibitors, one with a Ca-channel blocker, and three with a
combination of ACE-inhibitor and Ca-channel blocker for hypertension. The
presence of macroangiopathy was defined as a positive history for cardiovascular
events (angina, myocardial infarction), or intermittent claudication associated
with one or more absent foot pulses.
For Study III 52 adult type 1 diabetic patients were recruited in a consecutive
manner. Of them, 21 were on ACE inhibitor medication. One patients was on
dialysis. Seven normoalbuminuric, eleven microalbuminuric, and nine
nephropathic patients had undergone retinal laser treatment. Eleven patients were
smokers (21%). Blood pressure was measured in the right arm in a sitting
position by use of a calibrated mercury sphygmomanometer after a 5-minute rest.
Systolic (Korotkoff I) and diastolic (Korotkoff V) blood pressure was measured
twice and the mean value used in analyses. The control individuals were recruited
from the hospital and laboratory staff. None of them showed any signs of acute
or chronic illness.
The recruitment criteria for Study IV were a minimum age of 7 years at the
Hospital for Children and Adolescents, and 10 years at the Aurora Hospital, and
diabetes duration of at least 3 years. Thirty-nine healthy subjects were recruited
for a single timed overnight urinary sample for AER, TGF-b1 and a1-
microglobulin measurements. Altogether 113 patients (53 from the Hospital for
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Children and Adolescents and 60 from the Aurora Hospital), were included in the
study. Exclusions numbered 73, because either no sample for TGF-b1
measurement or an inadequate number of overnight urine collections for AER
measurement were avaílable. Neither glycemic control, duration of diabetes,
insulin dose, nor serum creatinine differed between the included and excluded
patients. At the Hospital for Children and Adolescents blood pressure was
recorded at three consecutive visits at 3-month intervals in a sitting position by an
automatic device (Dinamap Critikon, Tampa, FL). TGF-b1 and a1 microglobulin
were analyzed from a single urine sample.
ETHICS
The study protocols were approved by the Ethics Committees of the Hospital for
Children and Adolescents, of the Aurora Hospital, Helsinki, of the Department of
Medicine, University of Helsinki, Helsinki, Finland, and of Guy's Hospital,
London, UK. An informed consent was obtained from the participants.
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METHODS
NAT2 GENOTYPING (I)
The fast acetylator allele NAT2*4 and three slow acetylator alleles NAT2*7B,
NAT2*6A, and NAT2*5B were detected by a method developed earlier (Abe et al.
1993). DNA samples were either dried EDTA-blood on blotting paper (Lin et al.
1993), or DNA extracted according to standard procedures. The 559-basepair
NAT2 genomic sequence was amplified by two oligonucleotide primers: 5'
TGACGGCAGGAATTACATTGTC and 3'ACACAAGGGTTTATTTTGTTCC.
The PCR mixture contained a DNA template, 10 pmol of each primer, dNTPs
200 µM, 10 mM Tris-HCl, pH 8.8, MgCl2 1.5 mM, KCl 50 mM, 0.1% Triton X-
100, and 1.0 unit Taq DNA polymerase (Dynazyme, Espoo, Finland) in a final
volume of 50 µl. Negative controls, either without a template or primers, were
present after every 12 samples. The mixture was incubated for 5 minutes at 95°C,
and then at 80°C for as long as Taq DNA polymerase was being added to the
reaction tubes. The "Touch down" PCR method (Don et al. 1991) was applied to
the blotting paper samples, where the following conditions were used:
denaturation at 94 °C for 1 min, annealing for 1 min at decreasing temperatures
from 65 until 55 °C, and extension at 72 °C for 1 min followed by a final
extension period at 72°C for 7 min. For amplification, 35 cycles were performed
by a programmable heat block (Perkin Elmer Cetus, Norwalk, CO, USA). For
extracted DNA, amplification conditions were: denaturation at 94° for 50
seconds, annealing at 55°C for 50 seconds, extension at 65°C for 50 seconds,
with 30 cycles until the final extension period.
After amplification, a mixture of 5 units of Asp 718, BamHI and TaqI
(Boehringer Mannheim, Mannheim, Germany) was added in 10 µl aliquots of
samples. The tubes were incubated at 37 °C for 3 hours and at 65 °C for 1 hour.
The digestion was halted with 3 µl loading buffer in each tube. The digested PCR
products were electrophoresed at 80 V for 2 hours on 3% Nusieve GTG agarose
(FMC BioProducts, Rockland, ME, USA) mini gel containing 0.5 X TBE and
1:20,000 ethidium bromide (10 mg/ml). The DNA marker was ø174 DNA/Hae III
marker (Promega, Madison, WI, USA), and alleles were recognized by distinctive
allele fragments.
NAT2 PHENOTYPING (I)
Urinary 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 1-
methylxanthine (1X) were measured by high-performance liquid chromatography
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(HPLC) after caffeine ingestion. After emptying the bladder, each patient
ingested caffeine 1-2 mg/kg. After 2 hours the bladder was emptied again, and
urine collected for the following 2 hours. Urine sample pH was lowered to 3.5
with acetic acid (Lloyd et al. 1992), and the aliquots were stored at -20°C until
analyzed.
Seventy µl (7 µg) of internal standard (4-acetamidophenol, Sigma, St. Louis,
MO, USA) stock solution and 120 mg of ammonium sulphate were added to 200
µl of urine in a 15 ml centrifuge tube. The tube was mixed for 15 s. The
metabolites were extracted with 6 ml of chloroform-isopropanol (95:5, v/v) by
mixing for 30 s. Following centrifugation at 2,400 rpm for 5 minutes, the organic
phase was transferred to another tube and evaporated under N2 in a 40°C water
bath. The dry residue was resuspended in 400 µl of 0.1% acetic acid, and 20 µl
was injected into the HPLC column. The extracts were analyzed by the isocratic
HPLC method (Grant et al. 1984) by an automatic Shimadzu LC-6A HPLC
chromatography system with a UV-detector (Shimadzu Corporation, Kyoto,
Japan). The reverse-phase column was Superspher 60 RP-select B (244 × 4 mm
I.D., 4 µm) with a precolumn (10 × 5 mm I.D., 5 µm), both from Merck,
Darmstadt, Germany. The mobile phase was made up of 0.05% acetic acid-
methanol (88:12) at a flow-rate of 0.8 ml/min and monitored by ultraviolet
absorbance at 280 nm. The stock solutions were 100 mg/ml AFMU in 0.1% acetic
acid, 100 µg/ml 1X in distilled water, and 100 µg/ml internal standard in
chloroform (Klebovich et al. 1993). The molar ratios AFMU to 1X were
measured, and any ratio under 0.3 was classified as slow acetylation. Intra-assay
coefficients of variation (n=9) were 5.9% for AFMU and 1.7% for 1X, and
interassay coefficients of variation (n=5) were 2.9% and 1.8%, respectively. One
chromatographic run was excluded because of its wide AFMU peak. AFMU was
generously provided by Dr. G. Philippossian of Nestle, Vevey, Switzerland.
ANTIBODIES TO OXIDIZED AND GLYCATED LDL (II)
Antibodies to oxidized LDL were measured by ELISA with MDA-modified LDL
as an antigen and native LDL as control antigen as previously described (Vaarala
et al. 1993). MDA-LDL represents a prominent epitope of oxidized LDL
(Palinski et al. 1989). Antibodies to glycated LDL were measured by ELISA in a
manner otherwise similar to the ELISA for antibodies to oxidized LDL, but
glucose-modified LDL served as the antigen. Glycated LDL was prepared by
incubating native LDL in PBS containing 80 mM glucose in a nitrogen-saturated
atmosphere for 7 days at room temperature. The glycated LDL subfractions were
separated from the glucose-incubated LDL preparation by Sephadex-G25
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(Pharmacia) desalting columns. Native LDL was treated in the same manner in
the absence of glucose.
For ELISA, one half of a polystyrene plate (Nunc) was coated with native LDL
and the other half with either MDA-LDL or glycated LDL (0.5 µg/well in PBS).
The plates were incubated for 2 h at 37°C nd then overnight at 4°C. After being
washed four times with PBS  containing 0.05% Tween and 0.001% Aprotinin
(Sigma), plates were blocked with 2% human serum albumin in PBS for 2 h at
room temperature. Serum samples were studied as duplicates, and diluted 1:50 in
PBS containing 0.05% Tween and 0.2% human serum albumin. Samples were
incubated for 2 h at room temperature. After washing, alkaline-phosphatase-
conjugated rabbit anti-human IgG F(ab)2 (Jackson ImmunoResearch), diluted
1:3000 in PBS-Tween-human serum albumin buffer, was added for 1 h at room
temperature; 1 mg/mL p-nitrophenyl-phosphate (Sigma) in 50 mmol/L carbonate
buffer containing 1 mmol/L MgCl 2 , pH 9.8, served as the substrate. The reaction
was stopped with 1 mol/L NaOH after 30 min and the color was read at 405 nm.
The results were expressed as optical density (OD) values, and binding to
oxidized or glycated LDL was calculated by subtracting OD values for native
LDL from those for MDA-modified or glycated antigen, respectively. In both
assays OD values for the modified antigen correlated with the final calculated
values (for oxidized LDL; r =0.862, and for glycated LDL; r =0.861).
PBMC CULTURE (III)
Fresh heparinized venous blood was collected from each subject. PBMC were
separated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient
centrifugation (3,400 rpm for initial Ficoll centrifugation and 2,000 rpm for
washing). Mononuclear cells were washed three times in PBS and diluted to 1 x
106 cells/ml in RPMI-1640 supplemented with 5% pooled human AB+ serum
(Finnish Red Cross Blood Transfusion Service, Helsinki, Finland) and 2 mmol/l
glutamine. Two-ml tissue culture wells (Nunc, Roskilde, Denmark) were used to
culture 2 x106 PBMC at 37°C in a 5% CO2 humidified incubator for 48 hours
with and without phytohemagglutinin (PHA) at a concentration of 5 µg/ml. Cells
and supernatants were collected after 24 hours and 48 hours and stored at -70°C,
cells in UltraspecÔ solution (Biotecx, Houston, TX, USA).
For the lymphocyte proliferation test, 105 PBMC/well in 200 µl of medium were
cultured in quadruplicates with and without PHA at 5 µg/ml for 3 days with [3H]-
thymidine (µCi/ml) present for the last 16 to 20 hours of the culture time. [3H]-
thymidine uptake was assayed by a liquid scintillation counter. The stimulation
index (SI) was calculated by dividing the median value of PHA-stimulated cells
by the median value of unstimulated ones.
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REVERSE TRANSCRIPTASE-PCR FOR TGF-b1 mRNA (III)
Total RNA was extracted according to the UltraspecÔ procedure. The reverse
transcriptase (RT) reaction was performed from 8 µl of total RNA by the First
Strand cDNA Synthesis Kit (Pharmacia). cDNA samples were diluted serially at
1:5, 1:50, 1:500, and 1:5,000 (Halminen et al. 1997). b-actin served as a positive
RNA control with dilutions at 1:5 and 1:50. For TGF-b1, primers
5´GCCCTGGACACCAACTATTGCT and
3´AGGCTCCAAATGTAGGGGCAGG (Leung et al. 1992), and for b-actin,
primers TGA AGT CTG ACG TGG ACA TC and ACT CGT CAT ACT CCT
GCT TG (Melby et al. 1993), were used. Each set of samples had two negative
controls, one without TGF-ß1 primers, the other without a sample. ThePCR
conditions were as follows: hot start at 94°C for 2 minutes, 30 cycles with
denaturation at 94 °C for 1 minute, annealing at 62°C for 1 minute, and extension
at 72°C for 1 minute, and the last cycle with a final extension period for 10
minutes at 72°C. The PCR products were run on a 3% agarose gel (NuSieve
GTG, FMC Bioproducts, Rockland, ME, USA), stained with ethidium bromide
and photographed. Samples with at least one b- c in band were accepted for the
final analysis. Intra-assay variation was 11% for sample dilutions at 1:500 and
1:5,000, and 17% for dilutions at 1:5 and 1:50. Inter-assay variations were 21%
and 36%, respectively.
ASSAY FOR TGF-b1 (III-IV)
The concentration of TGF-b1 in the cell culture medium and in the urine was
measured by enzyme-linked immunoassay (Honkanen et al. 1997). The microtiter
plates were coated with monoclonal mouse antibody to TGF-b1-3 at 0.1 µg/well
(Genzyme Diagnostics, Cambridge, MA, USA). To activate latent TGF-b1,
diluted samples were incubated with 100 mmol/l HCl at 4°C for 2 h. Activated
samples were added to the wells for overnight. The detection antibody was a
chicken IgG-antibody reacting with human TGF-b1 (R&D Systems, Minneapolis,
MN, USA), followed by a sheep antibody to chicken IgG (Serotec, Oxford, UK),
and by an alkaline phosphatase-conjugated donkey antibody to sheep IgG
(Serotec). Natural human TGF-b1 (R&D Systems, Abingdon, UK) served as a
standard. The detection limit was 10 ng/L, but the lower limit for exact
concentration was kept at 70 ng/L. All assays were performed as duplicates. The
intra-assay and interassay coefficients of variation (CV) were 5.9 and 8.1%,
respectively.
ASSAY FOR a1-MICROGLOBULIN (IV)
A double antibody radioimmunoassay was developed for the determination of
a1-microglobulin. First, a1-microglobulin in urine competed with 125I-labelled
a1-microglobulin (Fitzgerald Ind., Concord, MA, USA) for binding to 500-fold
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diluted rabbit antibodies to human a1-microglobulin (Dako, Copenhagen,
Denmark). The antibody-bound a1-microglobulin was then precipitated by
adding Sepharose-anti-rabbit IgG (Pharmacia, Uppsala, Sweden). The samples
were centrifuged, and radioactivity of the pellets was measured. Standards were
purchased from Orion Diagnostica (Espoo, Finland). The sensitivity of the assay
was 0.05 mg/L, within-assay CV 3.9%, from day-to-day 5.1%.
CLINICAL LABORATORY TESTS (I-IV)
In Studies I and II, HbA1 was assayed by microcolumn chromatography (Isolab
Inc., Akron, OH, USA) in Helsinki, and by electroendosmosis (Corning
Chemical, Palo Alto, CA, USA) in London. In Studies I and IV, HbA1c was
measured by an instant immunological device (DCA-2000, Bayer Diagnostics,
Leverkusen, Germany) at the Hospital for Children and Adolescents, and by
HPLC (Diamat analyzer, Bio-Rad, Anaheim, CA, USA) at the Aurora Hospital
(normal range 4-6% with an interassay CV of 2-4% at both hospitals). In Study
III, HbA1c was determined by HPLC (Diamat Analyzer, Biorad Laboratories,
Germany, normal range 4.0-6.0%).
In Studies I and II, urinary albumin was measured by radioimmunoassay (Keen
and Chlouverakis 1963). In Study III, urinary albumin was measured by
radioimmunoassay (Albumin-RIA, Pharmacia-Upjohn, Uppsala, Sweden) with an
interassay CV of 4%. In Studies I and IV, urinary albumin was measured by
immunoturbidometry (Hitachi 911 Analyzer, Hitachi, Tokyo, Japan, at the
Hospital for Children and Adolescents, and Cobas Mira Analyzer, Roche
Diagnostics, Basel, Switzerland at the Aurora Hospital). Interassay CV was 9.7
% at 43 mg/L at the Hospital for Children and Adolescents, and 5.6% in the
range of 13-50 mg/L at the Aurora Hospital.
In Study III, serum glucose was measured by an automated hexokinase method
with a reference range of 4.0-6.4 mmol/L and an interassay CV of 2% (Hitachi
917, Hitachi, Tokyo, Japan). In Study IV, urinary creatinine was measured by the
Jaffe kinetic method (Hitachi 911, Hitachi, Tokyo, Japan). Urinary glucose was
measured by an automated hexokinase method with a normal value of <0.1 g/L
and an interassay CV of 2% (Hitachi 917, Hitachi, Tokyo, Japan).
STATISTICAL ANALYSIS
Differences in continuous parameters were tested by the Kruskal-Wallis analysis
of variance when more than two groups were compared, and by the Mann
Whitney U-test when two groups were compared (Studies I-IV). Differences in
genotype and acetylator frequencies and percentages between groups were tested
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by the Chi-Square test (Study I and III). Correlations were performed by the
Spearman test (Studies I-II), or by the Pearson test (Studies III-IV). Logistic
regression was used for calculating odds ratios and 95% confidence intervals for
nephropathy. Regression analysis for repeated measurements was used for
comparisons between the groups at two time-points (Study III). Multiple linear
regression analysis was used to explore relationships among multiple variables
(Study IV). For the Pearson correlation test and regression analyses those
parameters not normally distributed were logarithmically transformed. P-value
<0.05 was considered statistically significant.
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RESULTS
NAT2 POLYMORPHISM, SMOKING, AND TYPE 1 DIABETIC
NEPHROPATHY (I)
NAT2 allele frequencies in adult type 1 diabetic patiens
No difference was seen between adult type 1 diabetic patients and control
subjects in NAT2 allele frequencies (p=0.82), neither were there any significant
differences between normoalbuminuric, microalbuminuric, and nephropathic
patients, and control subjects (p=0.90). Allele frequencies did not differ
significantly between British and Finnish diabetic patients, respectively: the
frequency of NAT2*4 was 0.26 and 0.31, NAT2*7B 0.01 and 0.04, NAT2*6A
0.25 and 0.26 , and NAT2*5B 0.49 and 0.39 (p= 084).
NAT2 genotype and acetylator type distribution
The NAT2 genotype distribution was also similar in type 1 diabetic patients and
control subjects (p=0.33), as well as in the normoalbuminuric, microalbuminuric,
and nephropathic patients (p=0.86). No significant differences existed in the
proportions of fast and slow acetylators between the diabetic subgroups and
control subjects (p=0.71). The odds ratio of fast acetylators for microalbuminuria
and diabetic nephropathy was 0.94 (95% CI 0.54-1.64), p=0.84 by logistic
regression. British and Finnish subjects did not differ.
Effect of smoking
When the non-smoking and smoking diabetic patients were analyzed separately,
NAT2 allele frequencies differed significantly between the non-smoking
normoalbuminuric, microalbuminuric, and nephropathic patients, p=0.013 (Table
4). In addition, the proportion of fast acetylators differed between non-smoking
and smoking subgroups (Fig.2). In the normoalbuminuric group, the frequency of
fast acetylators was 33% among non-smokers, and 71% among smokers. The
corresponding figures for the microalbuminuric group were 68% and 45%, and
for the nephropathy group 52% and 42% (p=0.025). In non-smokers with a fast
acetylation capacity, the odds ratio for microalbuminuria and diabetic
nephropathy was 3.1 (95% CI 1.36-7.05), p= .007. In smokers, the
corresponding odds ratio was 0.31 (95% CI 0.08-1.2), p=0.09. The odds ratios
for non-smoking British and Finnish patients with fast acetylation capacity were
3.0 (95% CI 0.90-9.75) and 3.0 (95% CI 0.92-9.53), and in smokers 0.34 (95%
CI 0.05-2.13) and 0.21 (95% CI 0.02-2.22), respectively. In non-smoking patients
with long-duration diabetes (³23 years, median for these diabetic patients) the
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risk for nephropathy in fast acetylators was even higher 6.33 (95% CI 1.87-21.4);
p=0.003, but 1.53 (0.48-4.83); p=0.47 in patients with diabetes duration less than
23 years. Due to the small number of patients in the smoking groups, the effect of
the duration of diabetes was not possible to study.
Table 4. NAT2 allele frequencies in non-smoking (N) and smoking (S) diabetic patients
with subgroups of normal urinary albumin excretion (Normo), microalbuminuria
(Micro) and overt diabetic nephropathy (DN). Number indicates allele numbers in each
group.
NAT2
allele
(N/S)
Diabetic
patients
(99/46)
Normo
(48/14)
Micro
(28/20)
DN
(23/12)
Control
(37/15)
NAT2*4
Number
0.27/0.29
54/27
0.18 a/0.39
17/11
0.41 a/0.25
23/10
0.30 a/0.25
14/6
0.28/0.17
21/5
NAT2*7B
Number
0.03/-
5/-
0.04 a/-
4/-
- a/-
-/-
0.02 a/-
1/-
0.05/-
4/-
NAT2*6A
Number
0.26/0.28
52/26
0.35 a/0.21
34/6
0.18 a/0.33
10/13
0.17 a/0.29
8/7
0.26/0.33
19/10
NAT2*5B
Number
0.44/0.42
87/39
0.43 a/0.39
41/11
0.41 a/0.43
23/17
0.50 a/0.46
23/11
0.41/0.50
30/15
a p=0.013 by Chi Square test
NAT2 phenotyping in young type 1 diabetic patients
The AFMU/1X molar ratio (mean±SD) in 70 young type 1 diabetic patients was
0.54±0.04 for fast acetylators, and 0.13±0. 06 for slow acetylators (p<0.0001),
with a cut-off point of 0.30. The caffeine test revealed 41% to be fast and 59%
slow acetylators. The concordance rate between phenotyping and genotyping
tests was 97%. Two patients were slow acetylators according to the phenotyping
test but had only one recognizable slow acetylator allele: molar ratios 0.14
(NAT2*4/NAT2*5B) and 0.25 (NAT2*4/NAT2*6A). Fast and slow acetylator
genotype frequencies were 0.41 and 0.59 for normoalbuminuric patients (n=70),
and 0.80 and 0.20 for microalbuminuric patients (n=5), respectively. Fast and
slow acetylator frequencies did not differ between young type 1 diabetic patients
and adult Finnish control subjects (p=0.7). Neither age, duration of diabetes,
HbA1c, nor AER differed between fast and slow acetylators in this group of
young diabetic patients.
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Figure 2. A: Fast acetylators in the non-smoking subgroups of 99 type 1 diabetic
patients and 37 controls. Chi Square p=0.031. B: Fast acetylators in the smoking
subgroups of 46 type 1 diabetic patients and 15 controls. Normo, normal urinary
albumin excretion; Micro, microalbuminuria; DN, overt diabetic nephropathy; Control,
control subjects. Above the bars, percentages of fast acetylators, under the bars,
numbers of subjects in each group.
IMMUNE RESPONSE TO GLYCATED AND OXIDIZED LDL IN TYPE
1 DIABETIC PATIENTS WITH AND WITHOUT RENAL DISEASE (II)
The results regarding microalbuminuric patients have not been published earlier.
Antibodies to glycated LDL
The mean antibody level against glycated LDL was higher in diabetic patients
than in healthy subjects, but the difference was not significant (0.242±0.343 vs.
0.165 ± 0.22; p=0.14). Nephropathic patients had higher antibody levels to
glycated LDL (0.388 ± 0.459) than normoalbuminuric patients (0.258 ± 0.354),
or microalbuminuric patients (0.116± . 25), p=0.007 for the diabetic groups and
p=0.008 for all groups (Fig 3A). Microalbuminuric patients had significantly
lower antibody levels than nephropathic patients (p=0.004), but
normoalbuminuric and nephropathic patients did not differ from each other
(p=0.195). Antibody levels to glycated LDL did not correlate with HbA1 (r =-
0.033), or with AER (r =-0.012) in diabetic patients.
Antibodies to oxidized LDL
Antibody levels to oxidized LDL did not differ between the three groups, but
diabetic patients as a group had lower antibody levels to oxidized LDL than did
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healthy controls (0.150 ± 0.094 vs 0.180 ± 0.105 OD, p= .04) (Fig. 3B).
Antibodies to oxidized LDL correlated inversely with HbA1 n diabetic patients
(r =-0.193, p=0.02), and even more strongly in nephropathic patients (r=-0.460;
p=0.005). Antibodies to oxidized LDL did not correlate with AER (r=0.137;
p=0.092). Antibodies to oxidized LDL did not correlate with glycated LDL in
any of the groups.
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Fig 3A and B. Antibodies to glycated and oxidized LDL as optical density units (OD) in
normoalbuminuric, microalbuminuric, and nephropathic type 1 diabetic patients and in
healthy control subjects.
Normoalbuminuric patients had lower LDL cholesterol concentrations (2.7±0.8
mmol/L) than microalbuminuric patients (3.2±0.9), nephropathic patients
(3.2±0.9 mmol/L) or healthy subjects (3.1±0.7 mmol/L, p=0.003). LDL
cholesterol concentrations did not correlate with antibodies to oxidized LDL in
diabetic patients (r=0.010, p=0.4), but an inverse correlation was found between
LDL cholesterol and antibodies to glycated LDL (r=-0.194, p=0.016).
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In the nephropathic group, no significant difference was found in antibody levels
or in other laboratory or clinical parameters between patients with and without
macroangiopathy (Table 4). One patient in the normoalbuminuric group (2%), 13
patients in the microalbuminuric group (25%), and 18 patients in the
nephropathic group (49%) had clinical macroangiopathy.
Table 4. Presence of macroangiopathy in nephropathic patients, and its relation to
clinical and laboratory parameters.
Macroangiopathy
Yes No p-value
n 18 19
Sex (m/f) 8/10 9/10
Age (years) 39.9±9.2 35.8±7.7 0.153
Duration of
diabetes (years)
25.5±7.6 23.4±6.7 0.316
HbA1 (%) 9.6±1.7 9.8±1.4 0.557
LDL cholesterol
(mmol/l)
3.1±0.9 3.2±0.9 0.090
Antibodies to
glycated LDL
(OD)
0.353±0.506 0.421±0.421 0.438
Data are means ± SD
OD, optical density units
Antibodies to
oxidized LDL
(OD)
0.141±0.057 0.150±0.083 0.843
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TGF-b1 PRODUCED BY PERIPHERAL BLOOD MONONUCLEAR
CELLS FROM TYPE 1 DIABETIC PATIENTS WITH AND WITHOUT
DIABETIC NEPHROPATHY (III)
TGF-b1 mRNA expression
No differences were found in PBMC TGF-b1 mRNA expression between the
diabetic subgroups at either time-point. After 24 h culture, the unstimulated and
PHA-stimulated mRNA expression titers correlated significantly (r=0.31,
p=0.04). No correlation existed between TGF-b1 mRNA expression and HbA1c
nor between TGF-b1 supernatant and mRNA levels in the diabetic patients.
TGF-b1 secreted by PBMC
After 48 h culture, the highest TGF-b1 levels secreted by unstimulated PBMC
were found in patients with nephropathy (6.2 (0.9-20.0) ng/ml) when compared
to levels in patients with normal albumin excretion (4.1 (0.2-11.3) ng/ml), with
microalbuminuria (1.8 (0.2-6.4) ng/ml), and healthy controls (1.0 (0.2-7.0)
ng/ml); p=0.02 for the three diabetic groups and 0.006 for all groups (Fig. 4).
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Fig. 4. TGF-b1 levels secreted by unstimulated peripheral blood mononuclear cells
after 48 h culture in type 1 diabetic patients with normal albumin excretion (Normo),
microalbuminuria (Micro), overt nephropathy (DN), and healthy controls (Control)
(p=0.006 for all groups and 0.02 for the diabetic groups).
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The presence of PHA in the culture medium resulted in an increase in TGF-b1
protein secretion. The PHA-stimulated TGF-b1 levels of PBMC were 12.4 (2.9-
30.0) ng/ml in nephropathic, 7.3 (0.5-21.2) ng/ml in normoalbuminuric, 5.5 (0.5-
27.6) ng/ml in microalbuminuric patients, and 2.0 (0.4-17.5) ng/ml in controls
(p<0.05 for all groups and 0.05 for the diabetic groups, Fig. 5). Patients with
overt nephropathy differed from patients with microalbuminuria with respect to
their PBMC TGF-b1 secretion in both unstimulated and PHA-stimulated cultures
(p<0.05).
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Fig 5. TGF-b1 levels secreted by PHA-stimulated PBMC after 48 h culture in type 1
diabetic patients with normal albumin excretion (Normo), microalbuminuria (Micro),
overt nephropathy (DN), and healthy controls (Control) (p<0.05 for all groups and
0.05 for the diabetic groups).
When the unstimulated TGF-b1 levels at 24 and 48 h culture were analyzed by
regression analysis, PBMC from patients with overt nephropathy secreted higher
levels of TGF-b1 than PBMC from patients with microalbuminuria and normal
albumin excretion (p=0.004 and p=0.03, respectively), or from controls
(p=0.003) (Fig. 6). The unstimulated TGF-b1 levels were higher after 48-hour
than after 24-hour culture in 22 out of 52 diabetic patients compared to none of
the healthy subjects (p=0.004).
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Fig 6. The median levels of TGF-b1 secreted by unstimulated PBMC after 24 and 48 h
in type 1 diabetic patients with normal albumin excretion (Normo), microalbuminuria
(Micro), overt nephropathy (DN), and healthy controls (Control); (DN vs. Micro,
p=0.004; DN vs. Normo, P=0.03; DN vs. Control, p=0.003).
Correlation between TGF-b1 and clinical parameters
A correlation was observed between PHA-stimulated and unstimulated TGF-b1
levels and diastolic blood pressure in diabetic patients (r=0.3, p=0.03 for both),
and between unstimulated TGF-b1 levels and diastolic blood pressure in a
combined patient group with incipient and overt nephropathy (r=0.45, p=0.04).
PHA-stimulated or unstimulated TGF-b1 levels did not correlate with HbA1c (r=-
0.09, p=0.5; r=-0.12, p=0.4, respectively), or with AER (r=0.07, p=0.6; r=-0.04,
p=0.8, respectively) in diabetic patients.
Proliferation responses
No difference was observed in proliferation response of PBMC to PHA between
the groups (p=0.7 for all groups and p=0.6 for the diabetic groups).
URINARY TGF-b1 AND a1-MICROGLOBULIN IN CHILDREN AND
ADOLESCENTS WITH TYPE 1 DIABETES (IV)
Urinary TGF-b1
Type 1 diabetic patients had higher urinary TGF-b1 concentrations than control
subjects: 0.9 (0.05-122.3) vs. 0.3 (0.05-2.2) ng/mg creatinine (median (range)),
p=0.003. Microalbuminuric patients did not differ from normoalbuminuric
patients in TGF-b1 levels (p=0.4, Fig. 7). Urinary TGF-b1 correlated with the
concurrent urinary glucose concentration (r=0.2, p=0.03), and a1-microglobulin
concentration (r=0.2, p=0.02), but urinary TGF-b1 showed no correlation with
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HbA1c in patients with type 1 diabetes (r=-0.03, p=0.7), nor with age in diabetic
patients or controls. The mean systolic and diastolic pressure of three consecutive
visits, available in 51 diabetic patients, did not correlate with TGF-b1 (r=0.2,
p=0.1 for diastolic pressure and 0.2 for systolic pressure). AER or duration of
diabetes did not correlate with urinary TGF-b1. In the multiple linear regression
model containing a1-microglobulin and urinary glucose, neither of these
variables showed any independent association with urinary TGF-b1 with an
adjusted R2 of 0.04.
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Fig 7. Urinary TGF-b1 levels in children and adolescents with normal AER (Normo) or
microalbuminuria (Micro), and in healthy subjects (Control). A single value of 122
ng/mg creatinine in the microalbuminuric group is not visualized. Diabetic patients vs.
controls, p=0.003.
Of the diabetic patients, 43 (38%) had urinary TGF-b1 concentrations exceeding
the levels seen in the controls (over 2.25 ng/mg creatinine). In these 43 patients,
urinary TGF-b1 correlated with urinary glucose (r=0.6, p<0.001, Fig. 8), and 1-
microglobulin (r=0.6, p<0.001). The correlation between urinary TGF-b1 and
HbA1c was not significant (r=0.3, p=0.07). The correlation between urinary TGF-
b1 and mean systolic pressure was not significant (r=0.4, p=0.11). Systolic
pressure values were available in only 15 of 43 patients. In the multiple linear
regression model including a1-microglobulin and urinary glucose, a1-
microglobulin independently associated with urinary TGF-b1 (p=0.02) with
adjusted R2 of 0.35.
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Fig 8. Urinary TGF-b1 and urinary glucose in a subgroup of children and adolescents
(43/113) with type 1 diabetes and urinary TGF-b1 exceeding levels in healthy subjects.
r=0.6, p<0.001.
Urinary a1-microglobulin
Type 1 diabetic patients had higher urinary a1-microbglobulin levels than control
subjects: 4.8 (0.6-48.8) vs. 2.7 (0.8-11.6) µg/mg creatinine, p<0.001. In diabetic
patients, urinary 1-microglobulin correlated with urinary AER (r=0.2,p=0.02),
HbA1c (r=0.3, p<0.001), and with urinary glucose (r=0.5, p<0.001) in addition to
urinary TGF-b1. Multiple linear regression analysis of these four variables
showed that urinary glucose (p<0.001) and TGF-b1 (p=0.046) independently
influenced urinary a1-microglobulin levels (adjusted R2 0.28). HbA1c and AER
had no significant effect (p=0.07 and 0.08, respectively).
Urinary AER
In diabetic patients, urinary AER correlated with age (r=0.4, p<0.001), duration
of diabetes (r=0.3, p=0.001), systolic blood pressure (r=0.4, p=0.01), and urinary
a1-microglobulin (r=0.2, p=0.02). In the linear regression model including these
variables, duration of diabetes independently associated with AER (p=0.04).
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DISCUSSION
GENETIC FACTORS ASSOCIATED WITH TYPE 1 DIABETIC
NEPHROPATHY
The genes which carry the risk  for diabetic nephropathy are thus far poorly
identified, but it seems evident that the genetic background of diabetic
nephropathy is multifactorial. The candidate gene studies provide a confusing
picture with contradictory results partly due to a great  variation in the criteria for
cases and controls. The present thesis presents a new candidate gene for diabetic
nephropathy. Non-smokers with the fast NAT2 genotype had an increased risk
for incipient and overt diabetic nephropathy (odds ratio 3.1). Since the odds ratio
for smokers was the opposite (0.3), the overall result regarding NAT2 genotype
and diabetic nephropathy was negative.
None of the earlier studies regarding NAT2 polymorphism and diabetic
complications comprised separate analyses between the non-smoking and
smoking subjects (Madácsy et al. 1992; Neugebauer et al. 1994; Agúndez et al.
1996; Gawronska-Szklarz et al. 1997). As for smokers, the small number of
smokers limited the analyses, but results suggested that the risk for diabetic
nephropathy is decreased in smokers with the fast NAT2 genotype. This is a
logical finding, since the slow acetylation capacity may lead to slower
metabolism of tobacco-derived toxic substances and possibly to a higher risk for
diabetic nephropathy. NAT2 polymorphism may in part explain why the results
concerning smoking as a risk factor for diabetic nephropathy are inconsistent.
More difficult to explain is the metabolic mechanism of the association of fast
acetylation genotype with diabetic nephropathy in non-smokers.
A clue is provided by a study regarding insulin levels during an intravenous
glucose tolerance test in fast and slow acetylators with diabetes. In fast
acetylators the higher fasting insulin and first-phase insulin peak levels observed
(Burrows et al. 1978) may reflect a higher prevalence of insulin resistance among
fast acetylators. Since insulin resistance is linked with diabetic nephropathy (Yip
et al. 1993; Kikkawa and Kojima 1996), it is possible that our finding can be
explained by the association of fast acetylation capacity and insulin resistance.
An even more speculative explanation could be the possible role of NAT2 in the
metabolism of nephrotoxic agents in diabetes, such as advanced glycation end
products (AGEs). Formation of AGEs produces highly reactive toxic
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intermediates which remain partly uncharacterized (Bucala and Vlassara 1995).
Serum and tissue AGE levels correlated with severity of diabetic nephropathy
(Makita et al. 1991).
The mechanism behind the association of NAT2 gene polymorphism and diabetic
nephropathy may not rely on acetylation capacity. Linkage with a causal gene
near the NAT2 locus on chromosome 8p22 is possible. No genome-wide searches
have thus far been published suggesting susceptibility loci for type 1 diabetic
nephropathy. In type 2 diabetic nephropathy, a recent genome-wide study in
Pima Indians pointed out chromosomes 7, 3, 9, and 20 as containing loci
potentially linked to nephropathy (Imperatore et al. 1998). These do not include
the NAT2 gene on chromosome 8. However, the Pima Indian population differs
genetically from the Caucasian population. Although the distribution of NAT2
alleles among Pima Indians is unknown, it can be anticipated that it differs from
that in Caucasians. For example, prevalence of the D allele of an ACE
polymorphism is lower in Pima Indians than in Caucasians (8% versus 27.5%)
(Foy et al. 1996). The distribution of NAT2 alleles varies significantly in
different populations. Two distinct ethnic origins, Japan and Polynesia, produce
high percentages (88-93%) of fast acetylators (Clark 1985), whereas among
Egyptians and Israelis, percentages of fast acetylators are only 18 to 33%. An
interesting feature is that Japanese and Polynesians show an increased prevalence
of diabetic nephropathy not fully explained by conventional risk factors
(Simmons et al. 1994; Matsushima et al. 1995). Genes relevant to the
pathogenesis of diabetic nephropathy may differ in different populations.
Therefore, genome-wide searches in the Caucasian population with and without
type 1 diabetic nephropathy would be valuable, and could clarify the position of
NAT2 among other candidate genes.
The study of NAT2 polymorphism and diabetic nephropathy emphasizes an
important aspect of gene studies: the interaction of genes and environmental
factors. We showed that an environmental factor, smoking, confounded the gene
effect to the extent that no association could be seen without analyzing data
separately taking this factor into account. The question is whether these kinds of
confounding environmental factors have been taken into account in the gene
analyses regarding diabetic nephropathy. One example is diet, which can vary
with respect to dietary glycotoxins, lipid composition, sodium content, and
protein intake (Pinelli et al. 1999; Koschinsky et al. 1997; Ying and Sanders
1998; Toeller et al. 1997). All these factors play a role in the pathogenesis of
diabetic nephropathy. In addition, physical exercise and BMI may prove to be
important environmental factors associated with insulin resistance. It is not even
known whether poor but stable metabolic control is more beneficial than
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fluctuation of metabolic control. Therefore in genetic studies it would be useful
to characterize patients very carefully with respect to their diets, lipid levels,
exercise habits, BMI, and smoking. In addition to these patient characteristics,
the rate of nephropathy progression would be valuable to know.
IMMUNOLOGICAL FACTORS ASSOCIATED WITH TYPE 1
DIABETIC NEPHROPATHY
Antibodies to glycated and oxidized LDL
An altered immune response to glycated and oxidized LDL was found in diabetic
patients when compared to that in healthy individuals. However, antibody
responses to glycated and oxidized LDL were quite different, and these two
antibodies did not correlate with each other in diabetic patients.
Normoalbuminuric and nephropathic patients showed an enhanced immune
response to glycated LDL, but microalbuminuric patients resembled healthy
individuals. In contrast, antibodies to oxidized LDL were decreased in all
diabetic patients compared to levels in healthy individuals, but the diabetic
groups did not differ from each other.
Antibodies to modified LDL may reflect the extent of LDL modification in vivo
(Lopes-Virella et al. 1996). The percentage of glycated LDL in type 1 diabetic
patients is elevated (Klein et al. 1995; Posch et al.1999), and correlates with
glycemic control (Lyons et al 1986). In patients with poorly controlled diabetes,
LDL was more susceptible to oxidation than LDL from control subjects (Tsai et
al. 1994), whereas in patients with well-controlled type 1 diabetes, the opposite
was true (Jenkins et al. 1996). When oxidation of LDL was studied in type 2
diabetic patients, the percentage of glycated ApoB in LDL correlated with the
susceptibility of LDL to oxidation (Moro et al. 1999).
Antibody levels to oxidized LDL were decreased in diabetic patients in the
present study. In contrast, in patients of comparable age, antibodies to oxidized
LDL were 1.5-fold increased (Mäkimattila et al. 1999). Another study also found
increased antibodies to oxidized LDL in type 1 patients, but the patients were
younger and their duration of diabetes was shorter than in the present study.
Levels of antibodies to oxidized LDL correlated inversely with age in that study
(Festa et al. 1998). The two latter studies used copper-induced oxidation
compared to our MDA-induced oxidation in the preparation of oxidized LDL
antigen. MDA is one of the epitopes present in copper-oxidized LDL which
contains several other epitopes as well. This difference cannot explain the
discrepancy between findings of our study and the two other studies, since
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antibody levels to MDA-modified LDL are usually higher than antibody levels to
copper-oxidized LDL (Bellomo et al. 1995; Ahmed et al. 1999a).
We did not find a difference in antibody levels to oxidized LDL in nephropathic
patients with and without clinical signs of macroangiopathy. It is possible that the
small number of patients in each group, and the cross-sectional design of the
study has led to a false negative finding. In type 2 diabetic patients of 10 years
follow-up, antibody levels to oxidized LDL were not predictive of cardiovascular
events, but the authors speculated that the use of copper-induced oxidation of
LDL may have reduced the sensitivity of the study (Uusitupa et al. 1996). In non-
diabetic subjects, antibodies to MDA-modified LDL have been predictive for the
progression of carotid atherosclerosis (Salonen et al. 1992), and myocardial
infarction (Puurunen et al. 1994), but not for stroke (Ahmed et al. 1999a).
Alternatively, the mechanisms of atherosclerosis may differ at least in part
between diabetic atherosclerosis and common atherosclerosis.
An inverse correlation between HbA1 and antibodies to oxidized LDL was found
in our type 1 diabetic patients. This finding was repeated later by Festa et al.
(1998), who also found that antibody levels to oxidized LDL were lower in
patients with microvascular complications. The latter finding may in part result
from a difference in age and duration of diabetes between their patients with and
without microvascular complications (duration 22 vs.11 years), a difference
absent from our patients. However, immune complexes were found only in
patients with low antibody titers. Recently, antibodies to oxidized LDL were
found to be inversely related to coronary artery disease in the subsequent 8 years
of follow-up in type 1 diabetes (Orchard et al. 1999). In the same patients
circulating immune complexes (oxidized LDL vs. antibody to oxidized LDL)
were present, suggesting consumption of free antibodies (Lopes-Virella et al.
1999). Other circulating immune complexes, those containing antibodies to
cardiolipin were found in 83% of type 1 diabetic patients compared to 5% of
healthy controls. In patients with vascular complications, the prevalence of
circulating immune complexes was as high as 91% (Ahmed et al. 1999b).
Immune complexes may prove to be more important than free autoantibodies in
the pathogenesis of vascular complications. It is possible that in our study the
decreased antibody level in diabetic patients compared to that in healthy
individuals reflected the presence of immune complexes. An inverse correlation
between antibodies to oxidized LDL and HbA1 suggests that poor glycemic
control increases the formation of immune complexes and increases the risk for
diabetic complications.
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Few studies are available regarding antibodies to glycated LDL. Similarly to the
situation in normoalbuminuric and nephropathic patients in the present study,
antibodies to glycated LDL were increased in type 2 diabetic patients compared
to levels in healthy controls. However, antibodies to glycated LDL were not
associated with vascular complications (Bellomo et al. 1995). Neither could we
see any association of these antibodies with diabetic nephropathy or
macrovascular complications. Because the clinical characteristics of the type 2
patients differed from our type 1 diabetic patients, the results are not totally
comparable; the short mean duration of diabetes (8 years) resulted in a low
proportion of patients with incipient or overt diabetic nephropathy. It is, however,
evident that glycated LDL is immunogenic and may lead to autoantibody
production and formation of immune complexes (Witztum et al. 1983). Glycated
LDL enhances cholesteryl ester synthesis in human monocyte-derived
macrophages (Lopes-Virella et al. 1988). These two factors may be related to
atherogenesis in diabetes.
PBMC-secreted and urinary TGF-b1 in type 1 diabetic patients with and without
diabetic nephropathy
Two non-invasive means were used to study activation of TGF-b1 in diabetes.
PBMC isolated from patients with overt type 1 diabetic nephropathy secreted
higher levels of TGF-b1 than did PBMC from patients with normal AER or
microalbuminuria, or from healthy subjects. Urinary TGF-b1 was elevated in
one-third of young diabetic patients with normal AER. Neither PBMC-secreted
nor urinary TGF-b1 correlated with AER or glycemic control.
According to several studies, glucose is an important activator of TGF-b1. High
ambient glucose stimulates TGF-b1 bioactivity and gene transcription in cultured
glomerular epithelial, mesangial, and proximal tubular cells (Nakamura et al.
1992; Rocco et al. 1992; van Det et al. 1997; Hoffman et al. 1998, Han et al.
1999). Nothing is known about interindividual variation in response to ambient
glucose. In diabetes, plasma glucose varies according to diet, exercise, and
insulin treatment. This variation and its effect on TGF-b1 secretion could not be
studied in ex vivo isolated PBMC which were cultured in a constant 11 mmol/L
glucose concentration. In urinary TGF-b1 excretion, we observed an association
with simultaneous urinary glucose. However, this association seemed more to
reflect tubular dysfunction than a direct effect of glucose, because a marker of
tubular dysfunction, a1-microglobulin, and urinary glucose did not independently
predict urinary TGF-b1. In addition, the association between urinary TGF-b1
and urinary glucose was rather low.
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An interesting feature was the presence of low urinary TGF-b1 excretion in the
majority of young type 1 diabetic patients (62%), despite high HbA1c and urinary
glucose concentrations. Thus, in a substantial group of the diabetic patients,
hyperglycemia did not lead to increased urinary TGF-b1 excretion. Another
interesting feature was that PBMC from 22 of 52 (42%) diabetic patients secreted
increasing levels of TGF-b1 when secretion was measured at two time points,
after 24 and 48 hours culture. In contrast, PBMC isolated from healthy controls
did not increase their TGF-b1 secretion between the two time-points. Thus,
PBMC from over half the diabetic patients resembled that of healthy controls in
this respect. The reasons for these differences are not known, but genetic
regulation may play a role (Grainger et al. 1999).
Large interindividual variation in TGF-b1 secretion by PBMC was observed both
in patients and controls, as recently reported in healthy individuals at mRNA
level (Pociot et al. 1998). In diabetic patients these large in vitro diff rences in
TGF-b1 secretion cannot be explained by glycemic control, since HbA1c did not
correlate with TGF-b1 levels. The variation in urinary TGF-b1 excretion was
also high, and was not associated with glycemic control. This finding was in
accordance with a study performed in adult type 1 diabetic patients (Ellis et al.
1998). It is noteworthy that TGF-b1 is an important growth factor in many non-
diabetic fibrotic diseases such as cirrhosis of the liver, lung fibrosis, and
inflammatory kidney diseases (Border and Noble 1994). Recently it was found to
be involved in human atherosclerosis (Bobik et al. 1999). Perhaps the fact that
TGF-b1 is such a wide-spread growth factor can explain the lack of correlation
between TGF-b1 and the two key factors in the pathogenesis of diabetic
nephropathy (AER, glycemic control). Moreover, various growth factors and
cytokines may act together, boosting the combined effect, as observed concerning
IL-1b and TGF-b1 (Phillips et al. 1996), and TNF and TGF-b1 (Pawluczyk and
Harris 1998). Since other growth factors are also activated in the diabetic milieu
(Elliot et al. 1993; Di Paolo et al. 1996), have effects similar to those of TGF-b1
(Lupia et al. 1999; Johnson et al. 1992), and interact with TGF-b1 (Di Paolo et
al. 1996; Phillips et al. 1997), the relative importance of a single growth factor
may decrease.
One genetic polymorphism of TGF-b1, C509T in the promoter region of the
gene, has been shown to contribute to plasma TGF-b1-levels (Grainger et al.
1999). Another polymorphism of TGF-b1 has been shown to associate with
blood pressure. In a study by Cambien et al. (1996), one of the polymorphic
alleles, Arg25, when present homozygously, was associated with higher blood
pressure than was the Pro25 allele. This was confirmed by Li et al. (1999) in
hypertensive and normotensive patients. In addition, a correlation has been
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observed between circulating TGF-b1 levels and blood pressure (Li et al. 1999).
In the present study, a correlation was found in type 1 diabetic patients between
PBMC TGF-b1 secretion and diastolic blood pressure. The correlation between
systolic pressure and urinary TGF-b1 in a subgroup of patients with urinary
TGF-b1 above control levels was also rather high (=0.4),although not
significantly (p=0.11), probably due to the small number of patients. The
association of TGF-b1 and blood pressure is interesting, because patients with
overt nephropathy have a familial predisposition to essential hypertension
(Fagerudd et al. 1998). TGF-b1 production in these patients may be related to
their susceptibility to hypertension.
Hypertension is associated with increased intraglomerular pressure, which is an
important pathogenetic factor in diabetic nephropathy (Zatz et al. 1985; Hostetter
1994). Cyclic mechanical force causing mesangial stretching and capillary
expansion, which mimic glomerular hypertension, has been shown to stimulate
production of extracellular matrix in rat mesangial cells (Riser et al. 1992), and
TGF-b1 is involved in this process (Hirakata et al. 1997; Yasuda et al. 1996). In
type 2 diabetic patients urinary TGF-b1 correlated with degree of mesangial
expansion (Sato et al. 1998). The present study in young diabetic patients showed
an early rise in urinary TGF-b1 in one-third of diabetic patients with normal
AER, suggesting that an accumulation of extracellular matrix in kidney
mesangium may take place. Increased levels of PBMC-secreted and urinary TGF-
b1 can be seen as a marker for the capacity of an individual to produce TGF-b1,
a potentially harmful growth factor in relation to diabetic nephropathy.
Diabetic patients with microalbuminuria
Microalbuminuric patients showed lower TGF-b1 secretion by PBMC and lower
antibody levels to glycated LDL than did normoalbuminuric or nephropathic
patients. The main risk factors for diabetic nephropathy include duration of
diabetes, glycemic control, and hypertension. In both studies, duration of diabetes
was the same for microalbuminuric and for nephropathic patients. As shown in
Table 3, differences in glycated hemoglobin cannot quite explain the slower
development of nephropathy in microalbuminuric patients. Unfortunately, blood
pressure levels were not available in Study II. In Study III, nephropathic patients
had higher blood pressure than did microalbuminuric patients. The reasons for
the various rates of progression of diabetic nephropathy have not been fully
elucidated. Type 1 diabetic patients with microalbuminuria are generally
considered high-risk patients for overt diabetic nephropathy (Viberti et al. 1982;
Mogensen and Christensen 1984; Krolewski et al. 1985), although recently it has
been estimated that only about half the microalbuminuric patients will ever
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proceed to diabetic nephropathy (Krolewski et al. 1996). The risk for proceeding
to overt diabetic nephropathy is relatively low after long-duration diabetes
(Forsblom et al. 1992). Our results for microalbuminuric patients regarding
PBMC TGF-b1 secretion and antibodies to glycated LDL suggest that
immunological factors may modify the progression of diabetic nephropathy.
These factors can be regarded as indirect contributors rather than direct causal
factors.
PATIENTS AND METHODS
Patient and control selection and design of the studies
In Study I, patients and controls were either British (36%) or Finnish (64%)
Caucasians. This was a disadvantage in our study, because in candidate gene
studies, cases and controls should have similar genetic backgrounds (Witte et al.
1999). To ensure that our results were not due to a confounding effect caused by
population stratification (Witte et al. 1999), all the analyses were made separately
as well as combined for British and Finnish patients. No differences in the results
were evident.
Smoking history obtained from the patients and controls in Study I included the
current or >12-year smoking history in the past but not the amount of cigarettes
per day, duration of smoking, or pack-years (20 cigarettes per day equals one
pack-year; Benbow et al. 1997). It is difficult to evaluate whether this kind of
detailed information would have improved the reliability of the results. The group
of smokers was too small to make any dose-response analyses even had the pack-
years been available. A further disadvantage was that smoking data came from
only 197 individuals of 267 (74%).
Study II included 207 patients and controls of British and Finnish origin. The
levels of antibodies are known to be regulated by several factors including
environmental factors. Antibody levels to glycated LDL were higher in Finnish
than in British individuals, although the trends between the subgroups were
similar between the two populations. A uniform British or Finnish population
would have been preferable to the combined one in this study as well.
All the four studies were cross-sectional. Especially in Studies III and IV, several
follow-up samples and especially samples taken before and after the start of ACE
inhibitors would have furnished valuable new information.
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Laboratory methods
In Study I one three slow NAT2 alleles were analyzed out of the at least 12
currently identified (Vatsis et al. 1995). At the beginning of the study, however,
knowledge of the alleles was limited. The four alleles were reported to cover
approximately 95% of acetylation types (Hickman and Sim 1991), which was
confirmed by our own caffeine test performed in children and adolescents.
Therefore, the genotyping can be considered rather reliable to separate fast and
slow acetylators.
In Study II, antibodies to oxidized LDL were analyzed according to a method
developed earlier in our laboratory. Oxidized LDL was prepared by incubating
LDL with malondialdehyde, an end-product of lipid peroxidation. The
preparation of glycated LDL for antibody measurement was a difficult task. The
reason for the variation in the quality of prepared antigen after incubation of LDL
with glucose in a nitrogen atmosphere remains unclear. The antigenic epitopes
are poorly characterized for both oxidized and glycated LDL. No international
standards are available for these methods, and the comparisons of the results
between different laboratories are difficult to perform.
The measurement of TGF-b1 secretion by PBMC (Study III) cultured for 48 hour
is a biological assay which is influenced by multiple factors. PBMC were
isolated by Ficoll Hypaque gradient centrifugation which distinguishes red blood
cells under the Ficoll Hypaque layer, and mononuclear cells above it, and plasma
including thrombocytes is supposed to stay in the topmost layer. It has been
estimated that the yield of thrombocytes is under 0.5% of the total thrombocyte
count of the original blood sample when blood is obtained from a healthy donor
(Kanof and Smith, 1991). We performed no special procedures except washes by
PBS to purify the mononuclear cells. It is therefore possible that TGF-b1
released from thrombocytes has affected our results to some extent, since TGF-
b1 enhances its own mRNA production (van Obberghen-Schilling et al. 1988).
No correlation was observed between current thrombocyte levels and PBMC
TGFb1 secretion.
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SUMMARY AND CONCLUSIONS
Sustained hyperglycemia is a central predisposing factor for long-term
microvascular complications in patients with type 1 diabetes mellitus. Because
the level of long-standing glycemia does not fully explain the presence of
diabetic complications, it is possible that genetic or immunological factors can
protect against or predispose to microvascular complications. Our aim was to
characterize some genetic or immmunological features in type 1 diabetic patients
with and without early (microalbuminuria) or fully developed (overt) diabetic
nephropathy.
The methods included PCR with restriction fragment length polymorphism for N-
asetyltransferase (NAT2) genotyping, measurements of two caffeine metabolites
in urine by HPLC for NAT2 phenotyping, ELISA assays for measuring
antibodies to oxidized and glycated LDL and for measuring urinary transforming
growth factor-b1 (TGF-b1) from cell supernatants and urine. Peripheral blood
mononuclear cells were isolated and cultured to determine mRNA activation of
TGF-b1 and to quantitate TGF-b1 secreted by cells. Urinary a1-microglobulin
was measured by radioimmunoassay.
NAT2 gene polymorphism was investigated in 214 adult patients with and
without diabetic nephropathy. NAT2 is a cytosolic enzyme which participates in
the metabolism of certain drugs and foreign compounds in the liver. Several
polymorphic alleles of the NAT2 gene are known, and individuals are fast or
slow acetylators depending on their NAT2 allele combination. We found that fast
acetylators had an increased risk for early and overt diabetic nephropathy (odds
ratio 3.1; 95% confidence interval 1.4-7.1). This phenomenon was seen only in
non-smokers, which can be explained by the fact that smoking as such is a strong
risk factor for nephropathy and thus a confounding factor for NAT2.
Equal levels of antibodies to oxidized (MDA-modified) LDL were found in 153
diabetic patients with normal AER, microalbuminuria, and overt nephropathy.
Antibody levels for oxidized LDL correlated inversely with glycemic control, a
finding which was later repeated by Festa et al. (1998). The mechanism behind
this correlation may be related to immune complex formation leading to low
levels of free antibodies in patients with high levels of the substrate (e.g.,
glycoxidized LDL) for these antibodies. Antibodies to glycated LDL when
compared to other diabetic patients or controls, were lowest in patients with
microalbuminuria.
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To explore a possible genetic predisposition to high TGF-b1 production, we
studied TGF-b1 activation in peripheral blood mononuclear cells (PBMC) from
52 adult type 1 diabetic patients with and without diabetic nephropathy. TGF-b1
is considered a key cytokine mediator in various kidney diseases. It enhances
mesangial matrix expansion, which is a central event in diabetic
glomerulosclerosis. TGF-b1 secretion by PBMC was highest in diabetic patients
with overt nephropathy when compared to patients with normal AER and with
microalbuminuria, and healthy individuals. There was, however, considerable
overlapping between the groups.
Young type 1 diabetic patients (n=113) were studied for two urinary markers for
diabetic nephropathy: TGF-b1 and a1-microglobulin. a1-microglobulin is a
marker for tubular dysfunction. Young diabetic patients excreted elevated levels
of both TGF-b1 and a 1-microglobulin. One-third of diabetic patients with
normal AER had increased TGF-b1 excretion. Urinary TGF-b1 levels did not
correlate with any conventional risk factors for nephropathy, such as HbA1c or
duration of diabetes.
The following conclusions can be drawn from the Studies I to IV:
(I) In non-smokers, the fast NAT2 genotype may be a new risk factor for type 1
diabetic nephropathy. Smoking is a confounding factor in NAT2 analyses
regarding diabetic nephropathy.
(II) Elevated levels of antibodies to glycated LDL found in diabetic patients do
not seem to be associated with nephropathy or nephropathy-related
atherogenesis. Antibodies to oxidized LDL correlated inversely with glycated
HbA1-levels in type 1 diabetic patients. This suggests that hyperglycemia may
modify the circulating levels of these antibodies.
(III) PBMC from type 1 diabetic patients with overt nephropathy showed
increased TGF-b1 secretion, but in diabetic patients PBMC TGF-b1 secretion
did not associate with AER. PBMC TGF-b1 secretion correlated in diabetic
patients with diastolic blood pressure. These findings suggest that the TGF-b1
secretion measured from PBMC is not directly related to the pathogenesis of
diabetic nephropathy, but may reflect risk for vascular disease in diabetes.
(IV) Urinary TGF-b1 is increased in young type 1 diabetic patients. Urinary
TGF-b1 associated with two interrelated tubular markers: a1-microglobulin and
urinary glucose.
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